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Micro Array data contains the whole gene expression of a tissue, not a person as the 
gene expression of every tissue is different as different functions/genes are activated 
on each. Over the last years it has become a powerful tool in the diagnosis of genetic 
related diseases, and particularly cancer.  
This study has applied heterogeneous clustering techniques and defined consensus 
techniques in order to extract a robust partition from a Micro Array dataset. The 
different algorithms generate a variety of partitions which none of them is able to 
extract all the information that the dataset contains. Hence, it is required to find ways 
to combine these partial solutions in order to reach a comprehensive understanding of 
the dataset information. Existing methods in the literature underestimate the 
complexity of such process and suggest methods that do not cope with situations that 
arise from the combination of different solutions. 
At the same time, the available ground truth for the dataset used in the study cannot be 
granted full reliability what has made that the methods used are fully unsupervised. 
The ground truth has been considered, in the final results analysis phase, in order to 
have an estimate of the agreement with the oncologists diagnose. 
The data used is a Microarray dataset, GSE4290, from NIH database, with 180 
samples and 54613 probes (features) corresponding to a study on brain tumors. The 
approach used has been constructing a distance matrix from the dataset in order to 
reduce the dimensionality of the problem. 
In order to generate an ensemble of partitions, the clustering methods used have been 
chosen to be heterogeneous (Hierarchical Clustering, MSTKNN and Complex 
Networks based). For each of the algorithms used, a number of executions have been 
run with subsamples of the dataset. The results obtained for each subsample have been 
combined using an evolution of a well-known method for consensus clustering as is 
the work by Monti et al. in [1], that has been adapted to incorporate available 
information from the clustering methods used, in order to weight differently the 
partitions depending on their stability.  
In order to obtain a single partition the two more different results obtained from the 
three algorithms have been combined using robust consensus generating a unique 
partition that becomes the solution partition for the dataset. The experiment has been 
run for 6 different settings as the dataset has been normalized in several ways and two 
different distance functions have been applied.  
Finally, the robustness of the methodology proposed has been evaluated by repeating 
the experiments a number of times and the results compared among them using a 
battery of well-known similarity measures, both for the individual algorithm results 
and the proposed consensus solution. In addition, the variability of the different 
clustering methods has been measured using the membership coefficient of the 
consensus matrixes. The results show that the sought consensus occurs for one of the 
settings configuration used while the other configurations converge much later or do 
not converge at all. 
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The obtained partition has 6 clusters, one containing the whole control group, a second 
one containing most of the Oligoblastoma types and two others that split the 
Glioblastoma group. There are two small clusters with 5 and 1 samples respectively. 
The Astrocytoma group on the dataset has not been separated having a much smaller 
number of samples.  
The agreement of the result obtained with the physicians’ diagnosis has been measured 
using a modified Purity Index in order to consider, as it is the case, that the partitions 
obtained identify 2 subtypes of one of the brain tumor classes. 
As a direct application of the method, from the partitions obtained for the Microarray 
dataset GSE4290, it has been possible to identify the features (probes that correspond 
to genes) that better help to classify (diagnose) samples (patients) with several types of 
brain tumors.  
In order to achieve this, the features that explain the partitions have been extracted 
using the CM1 indicator and the results have been compared to other studies that have 
used the same dataset. The function of the genes identified corresponds, in a very high 
percentage, to genes related to oncological processes and metabolic pathways with an 
incidence in the development of the disease. 
The accuracy of 72% on the purity indicator is in the same level that the best results 
obtained in other studies using the same dataset. It is also in the same level of precision 
that several studies attribute to physicians when considering the varieties of tumors 
with higher degree of agreement in the diagnosis, Glioblastoma, while it significantly 
improves the diagnosis of other subtypes, for example Oligoblastoma. 
The results have been validated by an expert in biomarkers in order to support the 
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II.  BACKGROUND AND MOTIVATION 
The term Bioinformatics was coined in 1970 by Paulien Hogeweg[2] with a much 
narrower meaning that it has nowadays. The concept has broadened while maturing 
supported by other, also emerging, technical and scientific disciplines such as 
Artificial Intelligence, Genetics Engineering and the rest of bio-x fields that constitute 
a solid cluster where each pillar reinforces the others while benefiting from them in a 
perfectly harmonious symbiosis. 
Currently we can describe Bioinformatics as the discipline that using diverse 
computing technologies studies and provides the technologies to capture, store and 
analyze the information related to biological processes. Within this wide definition, 
genetics occupies a central space. 
Bioinformatics has experienced a magnificent progress in the last decade, as can be 
read in [3]. The cost and time required for DNA sequencing has been reduced from 30 
days and 100K$ to 1 day and 3K$. The focus is now on analysis of the data that can be 
obtained at such affordable price as it is estimated that the information retrieved in one 
month takes 5 months to be analyzed. Despite this staggering progress made on 
Bioinformatics, or because of this, it can be considered a young discipline, with many 
and ambitious challenges ahead. 
Some of these challenges, that have inspired and guided this thesis are, according to 
[4], (1) the processing of large-scale robust genomic data, (2) the interpretation of the 
functional effect and the impact of genomic variation, (3) integrating systems and data 
to capture complexity and (4) make results clinically relevant so that they are 
translated into medical practice. Underlying needs to achieve this as explained in [5], 
are, even now (13 years after publication), (1)the understanding of the sources of noise 
and variation in Microarray experiments, (2) the combination of expression data with 
other sources of information to improve their range and quality and (3) the 
reconstruction of networks of genetic interactions in order to create integrated and 
systematic models of biological systems. 
It has been my desire to take advantage of this Master’s Thesis to modestly contribute 
to the field in a way that it produces a benefit to society (even if just tiny). This desire 
is the outcome of a summer stay at the Hunter Medical Research Institute (HMRI) in 
Newcastle (Australia) where I have had the opportunity to be exposed and learn about 
the research projects in place at the Center for Information Based Medicine (CIBM) 
under the supervision of Prof. Pablo Moscato. The focus of most of such projects is the 
discovery of Biomarkers that assist in the diagnosis of diseases with a genetic origin 
and the selection of treatments for the different illnesses subtypes.  
Cancer, being one of the most fatal diseases at a global level, is the one being object of 








Gene Expression Microarray Data based experiments typically fall into three types of 
problems, according to [6]: “(i) identification of new tumor classes using gene 
expression profile – unsupervised learning; (ii) classification of malignancies into 
known classes- supervised learning; (iii) identification of marker genes that 
characterize the different tumor classes – feature selection.” 
From a bioinformatics point of view, as stated in [5]: “clustering methods are now 
more routinely being evaluated with respect to criteria such as robustness, 
computational cost, clarity of cluster definitions and reproducibility”, introducing the 
desirable characteristics of the algorithms. 
At the same time, Kleinberg, in [7], states that no clustering algorithm exists that can 
satisfy three basic properties (scale-invariance, richness, consistency) that are required 
in order to grant clustering results major trust. In opposition to the former, Zadeh’s 
theory in [8], relaxes Kleinberg’s axioms, although restricted to clustering methods 
where the number of clusters is provided, to the identification of Hierarchical 
Clustering with Single Linkage as the only method satisfying the three basic axioms 
defined (scale-invariance, order-consistent, k-richness). 
As a consequence of this, it comes that different clustering algorithms may generate 
very different partitions depending on their characteristics, what represents a limitation 
that adds to the lack of specific meaningfulness result of the unsupervised nature of 
clustering. 
In short, there is no guarantee on the kind of separation a clustering algorithm is going 
to generate. The only certainty is that it will, in a certain but unknown space, maximize 
the difference between members of different clusters while minimizing the difference 
between cluster members and that to a certain resolution, as the number of clusters 
may be different. The reason for that being the unsupervised nature of the process, 
there is no constrain in the kind of separation among samples that will be extracted. 
This being the case, it must be considered when analyzing a complex dataset using 
clustering, that the algorithm applied may not be able to extract all the relevant 
information implicit in the dataset. From this, it comes as a direct conclusion that it is 
necessary to apply a variety of algorithms and try to combine the results obtained from 
the different algorithms to produce a partition that represents all the groups in the data. 
Bearing in mind these guidelines, the objective of this work has been to define a 
methodology that can be used to obtain robust and reliable partitions of datasets from 
very heterogeneous partitions generated by different clustering algorithms applied to 
the same dataset. From the partition, the genes that help to explain the separation will 





IV. STATE OF THE ART 
Both clustering and bioinformatics are hot topics that have generated numerous 
publications. A comprehensive study of the state of the art on any of either topics or 
the combination of them would suppose an overwhelming effort that would consume 
the time this thesis is supposed to take. Hence, this section is a brief review of the 
literature in order to have a first insight of the current status of the field. It is then a 
best effort task that would require a deeper research in order to be considered 
complete, what is beyond the objective of this thesis.  
A. Microarray 
Genetic data commonly proceeds from Microarray chipsets. A Microarray chipset can 
be seen as a tray full of microscopic spots, called probes, containing, each, multiple 
identical DNA strands that match to one of the genes the human (or other organism) 
genome has. The human genome contains 21K genes. Several probes correspond to the 
same gene. The mapping of the probes to the matrix position in the Microarray surface 
is precisely registered. The manufacturing process of Microarray chips is alike to that 
of a microprocessor. 
The process of extracting a genetic signature of a certain tissue using Microarray 
technology requires a lot of steps involving manual processes and bio-chemical 
reactions making it quite sensitive. Rather than explaining the process how a 
microarray experiment is performed, what is not a core knowledge of this Masters, 
those requiring an explanation can view the following interactive and highly 
pedagogical tutorial available from Utah University[9]. 
http://learn.genetics.utah.edu/content/labs/microarray/ 
 
Figure 1 Tutorial on Genetics and Microarray Data 
From the explanations about the process it can be quickly observed that the process is 
far from exact and hence data proceeding from Microarray data is affected by high 
variability on its measures due to the many noise sources that along the whole process 
can affect the sample. 
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In this case, the Affymetrix Human Genome U133 Plus 2.0 Microarray chipset has 
been used. This chipset contains 54613 probes mapping to the whole human genome. 
Being well established the variability of Microarray experiments they are designed 
with normalization controls so that the measurements are tractable with a reasonable 
level of confidence that guides the researchers that use it to make the adequate data 
pre-processing of the information. 
Many techniques have been developed in order to address the main complexities 
inherent to Microarray data. From a sampling on the vast existing literature [10-13], a 
large group is related to Pre-processing (including Image Analysis), Normalization and 
Outlier detection. Other important problems addressed are related to the link of the 
biological information in the processing algorithm from the beginning in order to 
guide any search/combinatorial process involved. A third group tackles the different 
uses that the data can be given (class prediction, classification or discovery). Finally, 
the techniques are applied to specific problems (diseases / organisms). Clustering 
appears recurrently as an effective technique for class discovery and also related to 
feature selection as a means of validation of the extracted features. 
B. Clustering 
As aforementioned, clustering is the AI technique commonly used in Bioinformatics 
for class discovery. The literature provides many examples in which the use of 
clustering techniques have permitted to discover or re-discover, new subtypes of 
different diseases. In [14], Alizadeth et al. discover a new variety of lymphoma: “have 
conducted a systematic characterization of gene expression in B-cell malignancies” 
while, in [15] Golub et al., “A class discovery procedure automatically discovered the 
distinction between acute myeloid leukemia (AML) and acute lymphoblastic leukemia 
(ALL) ". 
The approaches taken to provide clustering solutions are of different nature: neural 
networks (SOM), spectral, genetic algorithms or probabilistic models are just some of 
the techniques applied to the problem.  
Some well-known state of the art studies have been published that summarize in a very 
comprehensive way the work done in this field. From [16] and [17], the following 





Figure 2 Classification of clustering methods 
If we survey [6, 10-13, 18] the clustering algorithms used in the study of 
Microarray(MA) Data we find that the most widely used are very traditional non-
sophisticated ones, like Hierarchical Clustering (HC) (in any of the linkage varieties) 
or among Partitional: the K-means family and Self Organizing Maps (SOM), as 
referred in[19]. A third approach is based on the application of component analysis 
and value decomposition (like PCA or SVD) to transform the data into a different 
feature space. It is very common also to apply Two-way clustering, consisting in 
clustering not only the samples but also the features (sometimes in an interdependent 
way) what helps in feature selection. Some other less traditional approaches have also 
been successfully applied to MA clustering like SQVT, a form of divisive HC, or 
kernel-PLS, a predictive model. CAST(Cluster Affinity Search Technique)[20, 21], 
CLICK(Cluster Identification via Connectivity Kernels)[21, 22], CURE[23] or 
PAM(Partition Around Medioids) [24, 25] are also examples that have appeared 
several times during the literature review either as methods to benchmark to or 
inspiration for new methods.  
Some clustering methods used in Bioinformatics, and in particular the ones selected in 
this work, are based on measuring the pairwise distance in the feature space of the 
samples to generate a distance matrix. A wide range of options have been proposed as 
distance functions to be used: Minkowsky[26] in any of its particular cases (Euclidean, 
Manhattan, Maximal), Mahalanobis[26] and Pearson( see section VI.B.2) or Kullback-
Leibler[27] are just some of them.   
In order to measure the quality of the results obtained a variety of metrics exists. These 
metrics fall into different categories. Graph measures are related to some variety of 
Modularity. Modularity calculates the difference between inter-cluster and intra-cluster 
edge weights, giving a measure of the modular structure of the network defined by the 
partition being evaluated. A general version of the Modularity that considers weighted 




Equation 1 Modularity 
where wij is the weight/strength of the edge connecting samples i and j, wx is the sum 
of all the edges of node x, 2w the sum of weights of all the nodes in the network (note 
that every edge will be added twice, what explains the 2 factor) and the δ(Ci, Cj) is the 
Kronecker function indicating whether samples i and j are in the same cluster. The 
higher the modularity value, the better is the partition.  
Supervised measures, also known as externally supported, are based on some 
calculation performed on the confusion matrix obtained by crossing the obtained 
partition with the ground truth for the data set. Mutual Information, Variation of 
Information, Jaccard Index, Rand Index, Mirkin Metric, Wallace Index and some 
Normalized and Adjusted versions of them are just a few examples of this family. On 
Appendix XI.D an overview of the main indicators and the ones used in this study is 
included. 
Among unsupervised methods, Silhouette [29-31] and Dunn [29, 32-34] are the most 
referenced ones. Both indexes are based on relationships among maximum inter-
cluster distances and some variety of maximum or average intra-cluster distance.  
In respect to metrics, [29] states, that any Cluster Validity Index chosen will be biased 
towards some of  the desirable properties of a cluster result (compactness, separability, 
connectivity) that may be different from the criterion applied by the clustering method. 
Hence, it is required to carefully choose any metric used for this purpose.  
The similarity with modularity methods is evident, the difference being that 
Modularity is based on weights among samples edges what does not require a 
complete connection among samples. Distances, in addition, can be seen as some form 
of inverse of weights, meaning that for two samples being on the same cluster, 
intuitively, it will be the case that there will be either small distances or large weights 
among the samples. 
Clustering, due to its unsupervised nature, is a common and powerful tool in 
bioinformatics as it provides a second diagnosis isolated from that obtained from other 
sources. The possibility of misdiagnosis, what is common even when made by highly 
qualified doctors, must be taken in consideration when analyzing the data. A brief 
summary of some papers on the reliability of tumor diagnosis by physicians can be 
found in Appendix XI.G. Both studies confirm the lack of consensus in glioma 
diagnosis with percentages of non-agreement typically around 30% in the best case 




C. Clustering methods 
The number of available clustering methods is endless as it is the literature about the 
topic. This study is based in three different Clustering algorithms that have different 
characteristics but that have something in common: the three can be applied to a 
distance or weight matrix for the dataset. 
1) Hierarchical Clustering(HC) 
Hierarchical Clustering (HC) is a wide family of algorithms rather than an algorithm 
itself. It has plenty of variants whose common ground is the fact that rather than 
generate a single partition, a series of nested partitions are obtained. The series of 
partitions are characterized for having strict borders, that is, if two elements are in 
separate clusters in the partition with k clusters, the same elements will always be in 
separate clusters for any partition with k’>k clusters. 
Naturally, a first classification of HC separates the methods in two groups, bottom-up 
or aggregative and top-down or divisive. 
a) Bottom-up methods 
Bottom-up methods start from the list of samples and at each step put together the 
closest two elements. The two elements are removed from the list and a new element 
(cluster) is added with distances to the rest of elements of the list calculated according 
to the selected linkage criteria. 
Several are the linkage methods most commonly used that can be classified in two 
groups. In the first linkage criteria group we find the methods Single, Complete, 
Average or Weighted Linkage. On the second group we find Centroids, Median and 
Ward linkage. See Appendix XI.D for a whole description and discussion of the 
methods. 
The first group has a common characteristic; they are computationally more affordable 
than the second group as all distance generation for the generated clusters can be 
generated from the original distance matrix. This makes the clustering calculation 
independent of the dimensionality of the feature space what in the dataset is very high 
and would introduce a computational overhead.  
b) Top Down methods 
In top-down methods the best partition at each step cannot be easily identified. Hence, 
many methods are based on search of a local optimum. Examples of top-down 
methods, as described in [6], chapter 4, are the Tree Structure Vector Quantization and 
Macnaughton-Smith.  
The former is based on K-means, as it is based on recursively applying a 2-means 
clustering to each obtained partition until the whole dataset has been separated in 
individual clusters. 
The latter is based on finding the point with greatest mean dissimilarity to other points. 
This point will be the centroid of the new group and the points in the group moved one 
at a time until no member is closer to the splinted group. 
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c) Disadvantages of Hierarchical Clustering 
In general, HC has been accused of important shortages compiled in [26] “ Kaufman 
and Rousseeuw (1990) commented that hierarchical clustering suffers from the defect 
that it can never repair what was done in previous steps. Morgan and Ray (1995) 
showed that hierarchical clustering suffers from lack of robustness, non-uniqueness, 
and inversion problems that complicate interpretation of the hierarchy.”  
2) Multi-resolution clustering based on complex networks 
The algorithm was first published in [28] , with subsequent enhancements  in    
[35] and permits evaluating the system being studied at multiple scales or resolutions. 
To make this possible, the diagonal of the correlation matrix is modified increasing the 
value in every iteration. Each iteration represents a new version of the network for 
which a partition is generated while the modularity of the network is optimized. 
The effect of modifying the diagonal of the correlation matrix is equivalent to adding a 
self-loop to each node whose weight is incremented along the process. The self-loop 
acts as a modifier of the node strength to become an individual cluster instead of being 
co-clustered with his neighbors. The effect of the self-loop in the whole network 
causes the emergence of different partitions for each self-loop value. 
The weight of this self-loop, referred as r, needs to be within a range that makes 
possible to create partitions that have from 1 to the total number of nodes clusters. 
Since we are modifying the network at each step there is no relationship among the 
modularity obtained for every iteration. 
The algorithm is non-parametric as the minimum and maximum required values for r 
can be automatically calculated. Both positive and negative weights can appear in the 
graph. R can also take negative values, even when the matrix is strictly positive, as it is 
the case. The higher r, the more clusters will appear in the partition obtained, although 
it is not monotonic and due to the stochasticity of the algorithms used there may be a 
decrease in the number of clusters as r grows, as can be observed in Figure 12. The 
increase on the number of clusters does not have a fixed slope and different regions 








Figure 3 shows the evolution on the number of clusters for the whole r spectrum of 
two examples in [36]. The number of clusters covers the whole range of number of 
partitions. The diverse plateaus show the size of the stable partitions in the dataset. 
3) MSTKNN 
MSTKNN[21] is a technique developed at the CIBM Research Centre. The algorithm 
is based on the intersection of two independently generated graphs. On one side, the 
Minimum Spanning Tree of the graph made by the pairwise distance matrix of the 
samples. On the other side, the k-Nearest Neighbor for the same base graph. For the 
second graph, k is defined automatically as the minimum k that makes the graph fully 
connected. The intersection of the two connected graphs does not need to be connected 
as in the generation of the MST graph, having to avoid the creation of loops will cause 
that different edges than the ones included in the k-NN graph are used. 
 
Figure 4 MSTKNN applied to the GSE4290 dataset 
The method, as can be understood from its definition, is highly variant depending on 
the samples. The separations in a result partition will correspond to the removal of 
edges that being in the MST graph where not in the k-NN graph. This means that the 
edge was not one of the k best edges. The weakest edges in the MST graph are the 
ones that the intersection process causes to disappear. 
In Figure 4, the result of applying the MSTKNN to the original dataset distance matrix 
can be seen. A total of 4 clusters are generated. Different node colors correspond to 
different sample diagnosis. 
This method is the one generating a wider variety of partitions when subsampling is 
applied as it depends a lot on the samples being clustered.  
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D. Consensus clustering 
With all this information, and recalling the introduction, it becomes necessary to find 
methods to combine the different partitions that are result of the different clustering 
algorithms that may be applied in order to obtain a 360º view of the dataset. 
A disruptive method, and widely adopted, for combination of multiple partitions is [1], 
that defines a method to select automatically the number of clusters that best represents 
the dataset. As this algorithm is the basis for the implemented in this study a more 
complete description follows. 
The algorithm takes a series of partitions of the same dataset and combines the 
partitions with the same number of partitions (k) into a single partition. To achieve 
this, a consensus matrix is computed, Equation 2, where each (i, j) position of the 
matrix corresponds to the ratio number of times in the same cluster for samples (i, j), 
M
(h)
(i,j), divided by the number of times in one of the dataset sub-samplings, I
(h)
(i,j) 
used to generate the range of partitions. The matrix is in the [0, 1] range, meaning for 0 
that the two samples are never in the same cluster, and for 1 that the two samples are 
always in the same cluster. 
 
Equation 2 Consensus Matrix 
From the consensus matrix for each k a Cumulative Distribution Function (CDF) is 
obtained. Each point on the curve indicates the number of elements in the matrix 
whose value is less than the abscissa value.  
 
Equation 3 Cumulative Distribution Function for consensus 
In a second step, the Area Under the Curve (AUC) of this CDF is calculated and 
finally the relative increment respect to the previous (or largest so far) k is computed. 
The method states that the best k to cluster the dataset corresponds to the one with 
greatest relative increase of the AUC. The relative increase is measured respect to the 
largest AUC for smaller k’s than the one being measured. 
 





Equation 5 Delta AUC 
In order to measure the stability of the clustering, the membership coefficient can be 
defined for each cluster according to Equation 6 and from the average of clusters for 
the whole partition. 
 
                   
Equation 6 Individual cluster membership coefficient 
   
 
 
 ∑     
 
   
 
Equation 7 Partition membership coefficient 
 
Figure 5 Data points, consensus matrixes and CDF from [1] . 
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Figure 5 shows for two synthetic datasets, the data points, the consensus matrixes 
obtained for the true k (k=5) and (k=4) and the AUC for all K’s, showing in yellow 
and blue the curves for the mentioned k’s. In the second row, the separation among 
clusters is clearer and so are the consensus matrixes and the differentiation between the 
consecutive AUC. For k>5 there is virtually no increase in the AUC. 
The algorithm has several drawbacks, as it is the need of visually inspecting the curves 
to assess if the first k (k=2 and ∆AUC= ∞ as it compares to 0) is a better partition 
than the best k obtained from the algorithm definition. This is not a problem in our 
case, where we want the process to be automatic, as our dataset has 5 different classes 
so any partition with only 2 clusters will not be relevant for our purposes as we expect 
to be able to differentiate at least 3 different large clusters in our dataset. If the best 
partition corresponds to k=2 we would not take it and consider instead the second best 
option, without this fact being relevant for our purposes. 
In order to resample the dataset, the authors suggest sub-sampling the feature set and 
taking subsets of the probes in the microarray matrix. Given that for this study the aim 
is to obtain the most representative biomarkers a different alternative will be used and 
the subsampling will be done for samples (patients). This, as will be shown, has some 
important benefits. 
The method assigns the same weight to all the original partitions what is far from 
realistic as some algorithms like K-means require K to be defined blindly and others 
like hierarchical clustering produce a whole range of partitions for any K but not all of 
them have the same stability, as will be discussed later. 
In [24], the authors differentiate between consensus clustering and robust consensus 
clustering and contribute a method who can produce both. The latter corresponds to 
the cluster that results from considering the strict assignment agreement of samples to 
the same cluster in several original partitions. The method permits combination of 
partitions from different algorithms. The weighted-kappa indicator is used, that is in its 
conception a supervised metric.  
In [37], a consensus method is proposed based on a probabilistic (and generative) 
model where the different partitions obtained from a selected clustering algorithm are 
averaged. The concept of refined consensus clustering is used to solve the complexity 
introduced when the consensus clustering presents heterogeneity, a concept that will 
keep some attention in this study. For the same topic, a solution is suggested in [38] 
that measures when the consensus matrix obtained can be merged. The main remaining 
problem for the approach is that no alternative is proposed other than discarding them.  
[25] is built directly on the work in [1], the method taken as basis in this study, to 
extend the method in order to make possible the combination of partitions from 
multiple algorithms by assigning arbitrary weights to the different methods. The 




In [29], the consensus algorithm incorporates a variable weight for each k, that is 
calculated from a Cluster Validity Index (i.e. Dunn, Silhouette,… ).  
The stability and accuracy of consensus clusters is largely improved respect to the 
average of the individual partitions generated by multiple runs of the same algorithms, 
as is stated in [39]. 
With all this information, it can be expected that the application of consensus 
clustering techniques helps to improve the result obtained by individual algorithms. 
Furthermore, key elements to be considered in the algorithm have been identified such 
as differentiated weighted partitions or the choice of appropriate Cluster Validity 
Indexes (CVI). 
Last but not least, the techniques found in the literature, [1, 24, 25, 37, 38] , have been 
successfully used with microarray datasets creating a solid ground to build the 





A. Main Characteristics 
Being restricted by ethical and regulatory constraints, a public dataset on brain tumors 
has been used for the study keeping in mind that the developed methodology should be 
able to be used in the future with other samples part of ongoing research for which a 
ground truth may not be available. 
The dataset is made of 180 samples (patients), with a control group of 23 individuals 
that have a diagnosis of epilepsy this implying that their brain is not a healthy one and 
some gene signature divergence may not be related to the disease being studied but to 
epilepsy disorders. 
The study has patients with 3 different types of tumors and, for two of the types, 
subtypes have also been identified. The classes and distribution can be seen in the 
following table:  
 
Table 1 Class distribution in GSE4290 
In [40], the authors define that clustering has some limits on the size of the partitions 
that can be identified. This resolution limit is defined as:  
  √  
being n the number of samples. In this study we have n=180 then l=13.41 
Given that for some of the subtypes, namely A2 and O3, the number of samples is 
below the resolution limit aforementioned, 7 and 12 respectively, for the study we will 
work with the Class Partition, with 4 main classes (C, G4, A, O) and a small group of 
Unclassified samples. 
The microarray platform used is Affymetrix Human Genome U133 Plus 2.0, that 
contains 54613 probes, providing complete coverage of the human genome, 21K 
genes. The complete technical description can be found here: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570 
While the number of samples in the dataset may seem small (for typical datasets in the 
AI data repositories) it is indeed quite large in the context of Microarray data and 
genetic studies. In the NCBI database, there are only 1210 that have 180 samples or 
Number Percentage Number Percentage
Control C 23 13% 23 13%
Glioblastoma Grade IV G4 77 43% 77 43%
Astrocitoma Grade II A2 7 4%
Astrocitoma Grade III A3 19 11%
Oligoblastoma Grade II O2 38 21%
Oligoblastoma Grade III O3 12 7%
Unclassified U 4 2% 4 2%











more out of 681.887 datasets for the species Homo Sapiens. This places the dataset in 
the 99.8 percentile in terms of number of samples. 
The existence of unclassified samples in the dataset is not negative by itself and may 
produce some benefits. While it is true that no category can be assigned to the samples, 
given that our dataset is relatively small, and considering that clustering is an 
unsupervised method, it has been decided to keep the samples in the dataset for our 
study. The reason is that these samples may help to create the solution partition either 
because they help to connect nodes, acting as bridges among them, i.e. two samples 
that are close to an unclassified sample may get clustered together when otherwise 
they would be separated and consequently they may be separated from other nodes. At 
the same time, if we didn’t use them, we should better go for a supervised technique 
and make full use of the available ground truth, with the required caution given the 
accuracy that can be expected from it. Chances are that these samples are particularly 
difficult to classify. 
B. Data Acquisition 
Microarray Data studies produce a CEL file, that contains the result of scanning the 
different samples, without any processing. For this study, the already pre-processed 
information has been used as without having access to the manufacturer tools and 
processing software making a good normalization is difficult although can be done and 
in some cases may be necessary, for example, if samples from different platforms must 
be compared as in [41].  
According to [42], the original study that made the dataset available, the dataset was 
processed following manufacturer defined protocol and using the manufacturer 
provided software in order to analyze very specific genes related to brain tumors: 
“the CEL files were normalized to a median-intensity array, and model-based 
expression values were calculated using PM/MM difference model. Based on the latest 
annotation from Affymetrix NETAFFX service, four probe sets for SCF(KITLG)gene 
were present in each chip. The signal intensities of each probe set were used for 
analyzing SCF (KITLG) expressions. The significance in differential SCF (KITLG) 
expressions in different grades of gliomas versus human non tumor brains was 
determined using log2-transformed expression values by standard unpaired two-tailed 





The method proposed has the following process pipeline, which will be explained in 
detail in this chapter. The first row, acquisition, with green background, corresponds to 
the process performed by the authors of the dataset. The rest of the sections have been 
developed as part of this study. 
 




The pseudo-code of the data would be as follows: 
multiClustering_consensus( no_outliers, Jensen-Shannon,[row_normalization]: bool; 
                                           N_times, N_iterations: integer 
                                           ground_truth: partition) 
 
if no_outliers then 
data=RemoveOutliers(MAD>5, data) 
if Jensen-Shannon then 
if row_normalization then 
data=RowNormalize( data, sum=1) 
data=ColumnNormalize( data, sum=1) 
distanceMatrix=Jensen-Shannon( data ) 









repeat N_times:  // for statistical significance 
         // hierarchical clustering 
         hcSubDistanceMatrixArray = subsample(N_iterations, distanceMatrix)  
         hcCluster = consensuate(hcSubDistanceMatrixArray) 
         // mstknn 
          mstknnSubDistanceMatrixArray = subsample(N_iterations, distanceMatrix) 
         mstknnCluster = consensuate(mstknnSubDistanceMatrixArray) 
         // cn 
         modularityCluster = consensuate(N_selections, modularityClusterArray) 
         cl1, cl2 = two_more_differents ( hcCluster, mstknnCluster, modularityCluster) 
         cluster = robust_clustering(cl1, cl2) 
         update_variability_internal (cluster) 
         update_variability_external(cluster, ground_truth) 
 
cm1=feature_extraction(cluster) 
domain_analysis(cluster, cm1, ground_truth) 
 
 
Table 2 Pseudo-code for processing pipeline 
A. Pre-processing: Outliers filtering 
Even after the pre-processing in the acquisition phase, microarray data has a very high 
variability due to the process required for its generation. It is then necessary to 
consider as a first step in the process to filter the features used in the analysis. 
Because the number of samples is reduced, and more if we consider the number of 
samples for each class, this process is very sensitive and its convenience needs to be 
carefully considered. The reasons are that different subclasses may have different 
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distributions particularly in those probes (genes) that explain the classification as quite 
often what causes a disease is an over-expression or under-expression of a set of genes 
and this miss-expression can be considered an outlier. Adding that the class 
distribution is unbalanced makes, intuitively, that what from one perspective can be 
seen as an outlier, from other perspective is an essential feature in our analysis. 
Despite this, we have wanted to see the influence of adding an outlier removal step in 
our processing pipeline and being able to compare the results obtained for both 
configurations. Nevertheless, being outlier detection a complex topic that could inspire 
a whole study, the strategy has been that of defining a single aggressive criteria and 
eliminating all those features that have a sample that classifies as an outlier under such 
criteria.  
By applying this, we will have two different datasets, one with the full set of features 
and a second one with a subset of the features after applying the outlier detection 
criteria. 
The criteria defined to consider a data point a feature is based on the Relative Mean 
Absolute Deviation (RMAD) that is calculated for each of the features independently. 
A data point will be considered an outlier if its RMAD is greater than 5.  
MAD is defined as:  
 
Equation 8 Mean Absolute Deviation 
where m(X) corresponds, for our case, to the mean of the distribution. RMAD will be 
obtained dividing MAD by m(X). 
MAD is related to standard deviation for normally distributed data: 
             √
 
 
     
Equation 9 MAD to Standard Deviation conversion for normal distributions 
Our factor RMAD=5 would translate, if the distribution was normal (what it’s not 
claimed) to σ=6.2666. A high σ is not synonym of outlier more when the distribution 
cannot be considered Gaussian but gives an idea of the criteria being applied. 
Calculating the number of features that would remain in the dataset if the MeanAD 





Figure 7 Number of features below the threshold for MAD 
Applying this criterion, a total of 56.455 data points are considered outliers. These data 
points belong to 28.957 features, keeping then 25.656 features free of outliers. On 
average each feature removed will have less than 2 outliers, and based on this, the 
whole feature will be removed from our dataset as a first scenario definition variable. 
This method, that is quite aggressive given the low number of outliers per feature we 
have and the high number of features filtered, should guarantee that any outlier is 
removed and possibly other features are removed too. Despite the high number of 
features removed we expect to be able to cluster with reasonable results the resulting 
dataset. 
B. Pre-processing: Sample distance matrix generation 
The different features (probes) have a very diverse value range with differences of 4 
orders of magnitudes from 6 to 60K when measured across genes, Figure 8. If the 
range is measured for the gene expression of an individual the difference is in one 
order of magnitude, Figure 9. 
 





Figure 9 Histogram for the range of values for the sum of probes for the 180 samples 
Because of the high-dimensionality of our data, a common strategy in order to reduce 
the computing required for the processing of the dataset is to obtain a pairwise distance 
among the samples. As explained in the State of the Art section, the available options 
are endless.  
Two options have been chosen for this study. The first is the Jensen-Shannon 
Divergence (JSD), successfully used in microarray data studies [43, 44] and other 
domains [45], the second being Pearson Distance, that according to [46], happens to be 
used in 95% of the studies for them considered where cluster analysis is based on 
similarity.  
1) Jensen-Shannon Divergence Square Root 
Although Jensen-Shannon Divergence (JSD) was defined in [47], it is studied more in 
depth in [48] that has been the reference used in this study. Its formula is given by: 
                                            
Equation 10 Jensen-Shannon Divergence 
Where w belongs to [0,1], in our case w=1/2, and H is the Shannon’s entropy: 
      ∑       
 
   
 
Equation 11 Shannon Entropy 
The measure requires then X and Y to be probability distribution functions, that is, 
their components to be positive and sum 1.The formula can be generalized to consider 
any number of distributions X, Y with different weights for each element in the 
distribution. 
The JSD has important and useful characteristics for the type of data involved: (i) JSD 
is symmetric; (ii) it is non-negative; (iii) JSD is only 0 if the parameters are identical; 
(iv) JSD is well defined even if the distributions are not perfectly continuous, that is if 
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Xi vanishes without Yi also vanishing. In addition, its square root is a metric since it 
satisfies the triangular inequality: 
sqrtJSD(X,Y) ≤ sqrtJSD(X,Z) + sqrtJSD(Z,Y) 
Equation 12 Jensen-Shannon Divergence square root triangular inequality 
With these properties sqrtJSD becomes a very promising distance function for this 
study.  
a) Normalization (for sqrtJSD) 
As aforementioned, in order to apply sqrtJSD, it is required that the data meets certain 
requirements. The requirement is that the data columns (samples) must correspond to 
Probability Distribution Functions, that is, they must add to 1. 
In addition to this, in [1], it is stated that: “The data used [in their experiments] were 
row- and column-normalized (so that both rows and columns sum to 0 and have a 
standard deviation of 1). This is necessary when using consensus clustering with HC, 
because it yields well-balanced hierarchical trees, which can in turn be split into non-
trivial (i.e., non-singleton) clusters”. This normalization can be achieved following the 
method described in [49]. While it may be true that data so normalized, may generate 
non-trivial clusters, no evidence is provided in the mentioned paper that the results are 
more relevant. This type of normalization has then not been considered in our study. 
Also the requirements are different for the distance function chosen, sqrtJSD. 
The requirement of sqrtJSD being that columns add to 1, we could have just applied a 
column normalization dividing each data point by the sum of its column. While this 
would have allowed us to meet the criteria, the high different range of values that data 
has, causes that by normalizing to sum to unity we may be introducing variations in 
our data.  
A very simplistic test has been performed with synthetic data in order to confirm this 
hypothesis and measure the effect of it and an alternative normalization. The 
alternative normalization consists on row normalizing to sum to unity (same criteria) 
prior to applying the column normalization. By doing this additional step the high 
variability among features in the dataset is eliminated and the variability introduced by 
the column normalization is much less. The results measured with the synthetic dataset 
can be seen in Appendix XI.F Data Normalization tests. 
Despite this significant difference observed, because the row normalization is not 
usually considered in similar studies performed with Microarray data, it has been 
decided to apply both normalization cases (with and without row normalization prior 




2) Pearson distance 
Pearson correlation coefficient is among the most common measurements used to 
compare data distributions. First mentioned in [50], its definition is given, as shown in   
[51], by: 
 
Equation 13 Pearson Correlation Coefficient 
Where cov(X, Y) is the covariance, σX is the standard deviation of X, μX is the mean of 
X, and E is the expectation. Pearson is bounded [-1, 1] where 1 indicates that both 
distributions are perfectly correlated and -1 indicates perfect anti-correlation, with 0 
meaning both distributions being completely independent. 
The existence of ρ just requires the distributions to be bounded, what is our case, 
despite the high range difference among different samples. ρ is sensitive to outliers so 
it could be expected to have quite different results for the experiment settings with and 
without outliers in the study. 
From the Pearson Correlation factor, a distance can be calculated as: 
 
Equation 14 Pearson distance 
The obtained variable will be [0, 2] bounded, with value 0 meaning the two 
distributions are perfectly correlated (not necessarily equal) and 2 meaning the 




C. Pre-processing: Normalization and inversion 
In all cases, the obtained distance matrix will be [0, 1] normalized. The reason for this 
normalization is driven by several aspects. The normalization is a linear transformation 
and will not affect relative magnitudes of the distances, the order is preserved. This 
makes that the change has no effect for the clustering algorithms chosen: MSTKNN 
and Hierarchical Clustering with Complete Linkage.  In the case of Complex 
Networks, the change does not affect the Modularity calculation, since the pairwise 
distance is 0 when a sample is compared to itself, matrix distance diagonal, this being 
the case the r factor will compensate for the normalization as no offset is applied in the 
normalization. 
In addition, as the complex networks method requires weights instead of distances, a 
weight will be calculated from each distance by just inverting the distance. In this case, 
by applying the subtraction: 
           
Equation 15 Weight definition from distance 
Note that in the case of the Pearson distance we are obtaining the initial Pearson 
Coefficient with a change in scale because of the [0, 1] normalization. 
This has been chosen respect to: 
    
 
   
 
Equation 16 Alternate weight definition 
because the former maintains the [0, 1] normalization and it doesn’t introduce 
singularities/outliers when dividing by values close to 0 and maintains a distribution 
that it’s symmetric. 
 
Figure 10 Histogram for inversions proposed (left w=1/d, right w=1-d) 
The left figure in Figure 10 shows the histogram obtained for the latter option. Note 
the two red circled outliers. On the right, the histogram corresponding to the former 
option, that shows a (more) symmetric distribution and a Gaussian-like shape.  
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The data distribution for the distance matrixes obtained for all the settings used in the 
study can be seen in Table 3. The bar at 0.0 corresponds to the diagonal of the matrix. 





Table 3 Histogram of distance matrixes 
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D. Pre-processing: Resampling 
Because we need our results to be relevant it is required to be able to perform multiple 
executions of our algorithms. Some papers, including [1, 25], perform subsampling 
based on selection of features but since our objective is the detection of the relevant 
features for disease diagnosis that would become a source of variability and potential 
loss of interpretability since we are aiming for a very reduced number of genes to 
explain the different classes in the dataset. In general, though, the decision of 
subsampling features is arguable since it modifies the description of the samples and 
hence the problem being solved. 
Typically, when the number of samples is small, Bootstrapping can be used in order to 
generate a larger dataset. As the methods used are based on distances, adding a copy of 
the same element does not increase the dataset as the added elements would be 
identical and the distances are equal to 0 respect to the cloned samples. Then, it is not 
an alternative in this case. 
We need then to subsample our dataset in the traditional way, taking a subset of the 
samples. The size of our subsampling instances has been decided to be set to 160, 
leaving out 20 samples on every iteration, roughly 10% of the total dataset.  
The subsampling is intuitively the more effective way of having different nodes 
networks since it removes samples from the complete original network. This 
modifies/moves the hubs present in the network and really permits the clustering to 
generate partitions that can be very different. In particular, for MSTKNN the 
resampling generates partitions with very different number of clusters. The effect is 
also significant in the case of Hierarchical Clustering, as the Complete Linkage is 
used. In both methods, as part of the calculation, the most distant elements become the 
seeds/hubs that generate the clusters, based on the minimum or maximum distance 
respectively. 
E. Clustering 
For the purpose of the study, three clustering methods have been chosen. The three 
methods are based on dimensionality reduction and from the feature space the pairwise 
distance among all samples is used instead. All the methods chosen are non-
parametric. Other than that they have different characteristics. Table 4 summarizes the 
characteristics of the different algorithms. “Stochastic” refers to the algorithm 
generating different results for the same data. “Edges” refers to the meaning of the 
connections between samples that could be distances or weights. “K” indicates if the 
algorithm generates one partition or a series of them.  
These algorithms have been chosen because having different characteristics they were 
candidates to generate discrepant partitions. Any algorithm could be included in the 
study if the proper adjustments are included in order to weight the different partitions 
obtained when the algorithm is executed several times for different subsets of the 
datasets. In this case, all the algorithms implemented are based on pairwise 
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Stochastic Yes No No 
Edges Weight Distance Distance 
K Multiple, non-nested Multiple, nested  Unique, automatic 
Table 4 Comparison of the different clustering algorithms 
1) Hierarchical clustering 
Based on the linkage methods described, the preliminary exploration of linkage 
methods has been restricted to the first group, more computationally affordable. An 




Figure 11 Dendrograms of the GSE4290 dataset for different HC linkages 
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The differences among the different methods are significant. Single linkage produces 
very small clusters that are aggregated almost in a 1 by 1 basis.  Although the colors in 
the x-axis show that the method can identify some meaningful structures, see the green 
and red labels concentrations, it is difficult to find a threshold cut that generates a 
partition not dominated by clusters with 1 sample only. Complete linkage is the one 
with less clusters of small size and that even with a cut threshold lower than the other 
methods, implying the partition is more relevant as differences among clusters are 
larger. 
From the graphs and based on its definition, it is immediate the agreement with chapter 
15 in [26], where the author states that both Single and Complete linkage are invariant 
under monotonic transformations of the distance matrix. This is not the case for 
Average as the same author defines neither it is for Weighted Average. The Complete 
Linkage has another advantage, the height of the dendrogram is fixed and equal to the 
maximum distance in the dataset, that is 1 for the whole dataset. Making an analogy 
with supervised learning, the fact that Complete Linkage is based on the maximum 
function, makes more difficult the existence of false positives, that is, samples that are 
very different to be put together.  
The Complete Linkage result used to decide shows three GB groups, what doesn’t 
confirm the hypothesis that the experts have about the dataset. If a higher threshold cut 
is specified, less clusters, then two of the GB groups are mixed with a group 
combining A and O samples. 
While this early design decision may, at a first glance, seem opposed to one of the 
methodological guidelines stated in [19]: “Don’t select the clustering method that 
gives the best result; class discovery should not be result driven.”, it is not our driver. 
To this respect, the result obtained by Weighted Average would be a better bias as it 
has the same four main groups that the final solution obtained shows. The Complete 
Linkage seems is a feasible option given that other options are not useful for the study 
based on characteristics not related to the results.  
Also the decision is based on observation of the dendrograms for one of the settings in 
the experiment while 6 different scenarios are considered in the study. 
2) Complex Networks based, modularity optimization 
The clustering method based on Complex Networks, requires significant computing 
resources even for small or medium size datasets like GSE4290. An exact result based 
on exhaustive search is only feasible for small and/or very sparse networks. Therefore, 
the algorithms used must be based on stochastic search. The resolution method chosen 
will be a sequence of algorithms all of them devoted to the optimization of the network 
modularity. 
The high cost is due to the fact that the algorithm is run once for each value of r in the 
interval selected. The interval is initially set to cover the whole scale of resolutions, 
meaning that the dataset will be split in partitions with a number of clusters from 1 to 
the total number of samples. The resolution of this scanning is a parameter of the 
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algorithm as can be the r minimum and maximum. If the r range is not specified the 
algorithm will find them. The rmin (the dataset clusters in 1 partition) is approximate 
while the rmax (the dataset clusters in partitions with 1 sample) is exact. The algorithm 
then finds the best clustering for each of the networks resulting from adding a self-loop 
of weight ri to the network where ri is given by: 
           
         
         
                   
Table 5 How r is obtained for each sample in the scanned range 
The result of each iteration will be a unique partition made up of a certain number of 
clusters. As previously mentioned, while in theory, the number of clusters should be 
increasing, the stochasticity of the algorithm may cause that there are points in which it 
decreases as r is increased. Figure 12 shows the evolution of the number of clusters for 
an execution of the algorithm. As an example, note that around r=45 the number of 
clusters decreases. 
Partitions for different values of r may be different even if they have the same number 
of clusters. Plateaus in the graph indicate the dataset stably partitions in that amount of 
clusters but not necessarily in the same way. 
As obtaining a high resolution on the whole range may be an expensive endeavor, it 
has been decided to limit the exploration to partitions with k<30. For the interval, 101 
equally spaced executions have been requested for each of the scenarios considered. 
As for the other methods, the initial dataset has been subsampled to create 100 
subsamples of 160 samples each. 
 
Figure 12 Evolution of number of clusters for GSE4290 dataset 
The problem then remains how to specify the rmax. to be used in each case without 
paying a tremendous computing effort. Since the r range is dependent on the sub-
dataset considered, ideally, it would be required to study the r-k relation for each case. 
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Since this is unaffordable, for each of the experiment scenarios, 5 sub-datasets have 
been randomly chosen and for each of them an execution of the algorithm has been run 
for the whole r range. From it, the minimum r such that k(r) ≥ 30 for the 5 cases has 
been chosen as rmax for all the executions.  
The choice of k=30 is driven by the analysis of Figure 12, note that around r=61 we 
have k=20 and this is the “tipping point” for a much faster increase of k. This indicates 
that any important partition will happen to the left of the graph. A safety margin has 
been added and then, instead of k=20, k=30 has been set for the executions performed. 
In addition, for k=20 or 30 the average size of the clusters in the partition will be 9 or 
correspondingly 6, what is also below the resolution limit of the problem and unlikely 
to provide any meaningful clusters. 
In summary, the sub-datasets generated for each experiment have been screened in the 
r interval expected to extract partitions with k in the range 1 to 30. 
The software package Radatools[52] has been used to perform the required executions 
for the study. The algorithm permits many different implementations that must be 
chosen based on the size and characteristics of the dataset. For this study, the number 
of nodes, 160, is too high for exact algorithms and the method used is a combination of 
3 different algorithms combined in a sequence of 4 steps: 
 Tabu search[53], consists on the move among existing clusters or segregation to 
a new one preventing, in order to constrain the number of options, the same 
nodes are moved repeatedly or reversed for a number of moves. The tabu 
constraint is not strict and tabu moves are allowed if they generate a solution 
better than the best generated so far.  
 Reposition[54], Kernighan-Lin algorithm, as described in [55], is based on the 
swapping of pairs of nodes to improve the modularity. As in the previous step, 
moves are locked for a period of time.  
 Newman fast algorithm[56], is in its conception an agglomerative Hierarchical 
algorithm but in the pipeline it takes the partition generated on the previous step 
and try to improve the modularity by merging pairs of the existing communities. 
 Reposition, same than step 2. 
3) MSTKNN 
This method generates a unique partition for each execution and hence is the simpler 
one to incorporate. For each execution on one subsample a partition with an 
unpredictable number of clusters will be generated. As an example, the distribution k 
for a round of 200 executions of the algorithm is shown in Figure 13. No assumption is 





Figure 13 Distribution of k for 200 subsampled executions of MSTKNN 
F. Intra-method consensus 
1) General process 
The idea behind consensus clustering, as explained in IV.D, is obtaining an average 
partition for each possible number of classes, k. For this, the algorithm chosen is 
executed a number of times and the partitions obtained merged. In [1], all the 
partitions receive the same credit what is not realistic since some clusters appear in a 
more natural way. The authors used k-means and HC. For the former, k must be 
provided as input to the algorithm and this is done blindly so the authors executed the 
same number of executions for all k’s. For the latter, the dendrogram was cut in the 
different partitions without retaining information about the cophenetic distance 
differences among consecutive partitions or any other information. The whole process 
relies then in the repeatability of the partitions at a certain k. There is no influence of 
the representability of the partition. The method proposed enhances the original 
method by assigning to each partition a weight obtained from the own method and that 
considers then the importance of the partition in the set of solutions obtained. The 
following subsections will clarify how the weights are obtained and what they 
represent for each of the algorithms considered. 
2) MSTKNN 
In order to obtain a consensus cluster for the MSTKNN a number of executions have 
been performed over a subsample of the dataset. As explained, the MSTKNN will 
generate a unique partition with a given number of clusters, K. 
Based on the consensus method explained in the State of the Art section, all the 
partitions with the same K will be added in a consensus matrix. The consensus matrix 
will have for each position i, j in the matrix the ratio number of times in the same 
cluster-number of times in the subsample. 
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As the algorithm generates partitions with a range of K’s, each of the consensus 
matrixes is created from a different number of generated partitions. 
Each of the consensus matrixes obtained will then be weighted based on the ratio of 
number of partitions in the set divided by the maximum number of partitions for the 
same k. Taking as example the k distribution in Figure 13, k=4 will have w=1 and k=5 
will have w=47/74. 
Despite the unbalance of the weights, it is not the case that the k with more results is 
the one that generates the larger ∆AUC. The reason is that the partitions generated by 
the algorithm are very heterogeneous and having more of them does not guarantee a 
better consensus. 
3) Hierarchical clustering 
In the case of hierarchical clustering, the result obtained from an execution is a 
hierarchy of clusters. As in the case of MSTKNN a consensus matrix will be generated 
for each K. As in the case of the Complex Networks algorithm, there is no interest on 
partitions with K>30, so the range will be restricted to this range. 
In this case, all the consensus matrixes will have the same number of components as 
every execution will contribute one partition to each consensus matrix. While in the 
case of ties in distances that condition wouldn’t have been true[57], the case has not 
occurred in the experiments, but it wouldn’t have any impact if it occurred. 
As an enhancement to the original algorithm, each of the partitions when added is 
weighted in order to consider the stability of the cluster in the hierarchy. The weight 
assigned is the difference among the dendrogram height (known as cophenetic 
distance) for the current partition, k, and partition k-1. This modulates the partition 
space giving more significance to partitions that keep apart clusters whose points are 
more separated.  
As the linkage method used is Complete Linkage and the data is [0, 1] normalized, the 
total height of the dendrogram will be close to 1. It is not 1 because the subsampling of 
the dataset may not preserve the [0, 1] normalization.  
By weighting this way, each of the consensus matrixes will have a different total 
weight (the sum of weights of the partitions included on it).The maximum total weight 
of the consensus matrixes will be used to normalize the weight of each in an analogous 
way to how it has been done for MSTKNN but in this case each partition instead of 
contributing a fix weight of 1, contributes by its cophenetic distance. The idea is like 
considering the cophenetic distance as weight for a partition and normalizing by the 
sum of all the dendrograms and then making sure that the consensus matrix with 
maximum value is multiplied so that the maximum value is 1. Then apply the same 
factor to all the consensus matrixes. 
4) Complex Networks, modularity optimization 
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Every execution of the algorithm generates a series of partitions with different number 
of clusters and often more than one partition will have the same number of clusters. 
Each of the generated partitions is the one that has been found to have a better 
modularity for an r interval. As in the case of HC, the partition has a weight, but 
differently there is more than one partition on each solution. Also, in this case, there is 
no guarantee that the solution generates partitions for all the number of clusters as the 
resolution used may not be enough to extract them. In summary every solution will be 
then a sequence of partitions where no assumption can be made about the k of each of 
them and where each partition is the best partition for an r interval. The sum of all the r 
intervals is equal to the whole r range scanned. Each partition will be then assigned a 
percentage of the whole r. 
The process defined for HC is then valid also for this other algorithm by assimilating 
the cophenetic distance to the r interval of the partition. 
G. Selection of the two more different partitions 
As a result of the previous steps, and calculating independently for each, the delta of 
AUC for the different k’s, we will obtain for each clustering algorithm (and settings) a 
k that is the consensus partition. The result obtained when applying the consensus, is 
shown in XI.B.6) for a run of 10 executions and 200 iterations.  With this, a partition 
will be generated for each of the algorithms, as can be seen, for different number of 
iterations in Appendix XI.B.6).  
As an example in Table 6 the best partitions for an execution (central column) are 
shown together side by side with the consensus partitions for k-1 and k+1. Blue lines 
in the central column indicate the partitions. The order of the samples has been 
preserved in the other cases so that the difference in the cleanliness of the partitions 
can be observed in addition to the Membership coefficient. Note that a better 
membership coefficient does not imply the AUC criteria will select that k, also the 
limitation of k>2 plays a role. 
The current step will receive as input the partitions in the central column and the two 
more different will be chosen to be combined in the following step. Since the 
similarity of the partitions can be measured in many different ways and the way it is 
measured may be related to how the clustering algorithm works, biasing the result, it is 
appropriate to use a battery of indicators. The measurements chosen are in Table 7 and 
its description in Appendix XI.E. 
The system then votes how many times a certain pair of partitions is the most different 
one. The pair that receives more votes is selected. Despite having a number of 
indicators that is multiple of the number of elements being compared during the 
experiments no ties have been produced. This is a circumstance that should be paid 
attention if the method wants to be generalized. 
The voting results for each of the settings with N_Iterations=500 can be seen in Table 









































Measure S/D Type 
Same Class Agreements Similarity Pairwise distance 
Disagreements Dissimilarity Pairwise distance 
Jaccard Index Similarity Pairwise distance 
Adjusted Rand Index Similarity Pairwise distance 
Fowlkes Mallows Index Similarity Pairwise distance 
Normalized Mutual Information Index (arithmetic) Similarity Entropy 
Normalized Mirkin Metric Dissimilarity Confusion matrix 
Normalized Van Dongen Metric Dissimilarity Confusion matrix 
Normalized Variation of Information Metric Dissimilarity Entropy 
 Table 7 Measures to choose the two more different partitions 
 




Column Norm + Jensen-Shannon 0 94 6 
Row + Column Norm + Jensen-Shannon 3 11 86 
Pearson 0 78 22 
WO 
outliers 
Column Norm + Jensen-Shannon 1 29 70 
Row + Column Norm + Jensen-Shannon 5 82 13 
Pearson 0 51 49 
Table 8 Voting of pair differences 
H. Inter-method consensus 
1) Discussion of existing methods 
In [25], the authors propose the combination of partitions generated by different 
algorithms in the consensus clustering [1]. They propose to do so without any 
consideration about the algorithms used or the difference among partitions. The 
method suggests that the combination of a number of partitions with the same number 
of clusters will produce also a partition in the same number of clusters. This, as the 
experiments have revealed, is not always possible, despite applying HC methods if the 
consensus matrixes have tied weights.  
Figure 14 shows an example in which two different algorithms generate perfect 
consensus matrixes for k=2 but the merge of the two matrixes cannot be clustered in a 
partition with k=2 without arbitrarily breaking ties. This situation cannot be avoided 
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since the partitions are initially grouped based on the number of clusters they contain. 
Paradoxically, the more robust the independent algorithm consensus matrixes are, the 
more likely is that the combination of them cannot be separated unambiguously. 
While is true that the case described is hiding that k is not the best option for the 
dataset, and in the example, k=4 is a much better option, the situation can also occur 
for the best k for the data when the two algorithms do not extract the same groups. 
Consider also that imposing a non-appropriate k to an algorithm does not mean the 
algorithm will generate more heterogeneous partitions; this will depend on the 
algorithm itself and the initialization parameters. While a properly designed algorithm 
should be able to behave inconsistently (generating different partitions) when k is not 
the natural for the dataset, and reducing AUC for k, this idea should be kept on mind 
when analyzing the results.  
Coming back to the main thread, when the original k is not suitable for partitioning, it 
would be required to find the proper k what brings the research to the original 
problem, deciding the “best k” for clustering the dataset. 
 
 
Figure 14 Separation not possible in the same K than original 
2) Proposed method for inter-method consensus: Robust clustering 
A more robust, and also conservative case, is robust clustering that permits to merge 
clustering results without any restrictions. Robust clustering obtains the intersection of 
the partitions provided 
The method could be used for any number of initial partitions (one for each algorithm 
involved) just by applying it iteratively over the result of the previous iteration. The 
a b c d e f g h a b c d e f g h
a 1 1 1 1 a 1 1 1 1
b 1 1 1 1 b 1 1 1 1
c 1 1 1 1 c 1 1 1 1
d 1 1 1 1 d 1 1 1 1
e 1 1 1 1 e 1 1 1 1
f 1 1 1 1 f 1 1 1 1
g 1 1 1 1 g 1 1 1 1
h 1 1 1 1 h 1 1 1 1
a b c d e f g h
a 2 2 1 1 0 0 1 1
b 2 2 1 1 0 0 1 1
c 1 1 2 2 1 1 0 0
d 1 1 2 2 1 1 0 0
e 0 0 1 1 2 2 1 1
f 0 0 1 1 2 2 1 1
g 1 1 0 0 1 1 2 2
h 1 1 0 0 1 1 2 2




more partitions used the more micro-clusters will be obtained as the method breaks the 
entry partitions according to intersection. 
The calculation of the intersection is the same that would be done to calculate the 
confusion matrix among the two partitions generating a cluster for each of the non-
empty crossings. The number of clusters this way obtained can be up to the product of 
the number of clusters in the original partitions. 
I. Feature extraction 
From our final partition, we need now to extract those genes that explain the difference 
between clusters. 
This can be done in a supervised or unsupervised way depending on whether the 
ground truth is considered or not. 
Considering the ground truth is equivalent to applying the Robust Clustering method 
to the obtained partition as if the ground truth was the obtained partitioned by another 
method (what actually it is: the physicians and pathologists method). 
It can also be the case that our dataset is only partially labelled and in this case the 
labelled samples can help to label the clusters based on their distribution. 
In order to select the differentiating features, the CM-1 indicator is used. CM-1 can be 
understood as an indicator, for each feature, of the relative difference among the 
averages for each class in the dataset. Those features that show a more extreme value, 
either lower (under-expressed genes) or higher (over-expressed genes), will be the 
ones that have a higher contribution to explain the partition. CM1 can be calculated in 
a 1-VS-1 way, that is comparing individual clusters or, in a 1-VS-all way, comparing 
each individual cluster against all other clusters in the partition. 
CM-1 is defined by the expression, as shown in [58]: 
 
Equation 17 CM-1 
J. Solution analysis 
In order to analyze the robustness of the solution, to measure the variability as the 
experiment is repeated a number of times, it is important to do it from different 
perspectives. In total three different measures have been done that are classified in two 
categories: external, where the ground truth is used, and internal, where the measure is 
done based on information in the own solutions. 
In addition, the solution has been compared to a supervised method, decision trees, in 
order to see if there is any degree of agreement in the features that are obtained by 
CM1 and the features used to generate the classification tree. 
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Last but not least, the resulting list of probes will be analyzed using Domain 
Knowledge in two ways. First, in a quantitative manner by comparing the results 
obtained with those in other studies using the same dataset and also using public 
databases on genetic relationship to diseases. Second, by an expert, to be able to 
benchmark the results with those found relevant in other published studies related with 
brain tumors. 
1) External robustness 
Based on the concepts of Purity, Homogeneity and Completeness a new indicator has 
been defined. This indicator is defined from the partition being evaluated and 
compared with the available ground truth.  
Since our ground truth is not only unreliable but also could become a limitation when 
trying to discover new diseases subtypes, supervised metrics for validating the 
goodness of the results are not fully appropriate and some modifications need to be 
introduced. 
The definition performs the intersection of the partition obtained with the ground truth 
obtaining, the confusion matrix of the two partitions.  
If the solution obtained for the first set of settings is taken, as shown in Figure 15 and 
Table 9, for each of the classes in the partition (1 to 6), whose size is above the 
resolution limit as defined in V Dataset (2, 3, 5 and 6), the majority class is identified. 
In [59], some desirable objectives for cluster assignment are defined: (1) homogeneity, 
each cluster only contains members of a single class; (2) completeness,  members of a 
given class are clustered in the same class. The formulas are explained in XI.E.10) 
 
 1 2 3 4 5 6 J 
C  23     0 
GB  10 3 2 33 29 15 
A 1 7 8 2 3 5 - 
O  9 32 1 4 4 18 
-  1   1 2 - 
Total - 50 43 - 41 40  




Based on this idea, two measures are calculated for each of the sub-clusters identified. 
The definition of the first one, reminiscent of Purity, and that we will call intra-Purity, 
is given by: 
       
 
    
          
                               
Equation 18 Intra-Purity 
that represents the average of elements that are in the same class that the majority class 
of each cluster in the solution partition intersected with the ground truth. 
The second measurement, called extra-Purity, is given, when classes in the ground 
truth are preserved, by: 
            
 
∑     
       
                              
Equation 19 Extra-Purity 
In the general case, of having a class split in two or more clusters being majoritarian 
the definition becomes a bit more cumbersome: 
    {               |     |    
that is, the subclusters of the ground truth class k that are not majoritarian in their 
respective clusters in C. Using as example the confusion matrix in Table 9. For class 
G, JG would be: 2, 3, 4 and from it the addition of corresponding cardinalities 
10+3+2=15. 
Then EP would be defined as: 
            
      
|   |  ∑          
 
Equation 20 extra-Purity per cluster 
where from the denominator we are excluding the samples belonging to the same 
cluster in the ground truth that belong to another majoritarian sub-cluster. 
 
                              





An example, based on Table 9, will help us to clarify the definition. For IP, we obtain: 
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Equation 22 Numerical example of the calculation of P, IP and EP 
With this definition we are introducing two biases in the calculation of EP when for 
the same class in the ground truth there are two clusters where the class is majoritarian, 
GB case, corresponding to the scenario of discovery of a new subclass not represented 
in the ground truth. The first bias is that we are not considering classification errors 
between the two classes, we are then favoring the measure as our ratio will be higher 
or equal than the real. The second bias is that any number of samples in clusters where 
its class is not majoritarian will punish all clusters where it is majoritarian. In this case, 
we are calculating a strictly lower measure than the real. On the other hand, the small 
clusters with size below resolution limit are not considered for IP measure and only the 
classes that become majoritarian in one cluster of the solution partition are considered. 
Also the Unknown samples, (-) in the table, will count as incorrect when calculating 
IP. As the measurements start from the majoritarian clusters, having an unbalanced 
dataset favors that the classes with a higher number of samples become majoritarian 
more easily. 
2) Internal robustness 
To measure the robustness of the solutions two different approaches can be taken. The 
first approach consists on measuring the similarity of the different solutions obtained 
among them pairwise. Note that typically this is an external method because the 
ground truth is used, to measure accuracy. In this case, robustness is being measured 
using the different solutions generated, this is why it is being considered an internal 
method. As in the case of choosing the two more different partitions obtained from the 
individual clustering methods, the same battery of indicators has been chosen. As in 
each experiment 100 executions are run, the pairwise comparison will generate 
100x99/2=4950 comparisons. The different indicators will be plotted separately in 
order to view the convergence of the results. Because the different indicators have 
different scales they have been separated in two groups when the results are shown.  
The second method measures the convergence of each of the algorithms. This is done 
based on the average of the membership coefficients for each cluster, Equation 7, of 
the consensus matrixes generated. Then, for each set of settings we will obtain three 
distributions, one for each of the clustering algorithms. This will help to know where 
the variability originates in the whole process and can be used to modify the selection 




3) Clustering vs Decision Tree 
In order to compare the two methods and given their different orientation the 
comparison has been made based on the features selected on the decision tree 
compared to the features extracted from the CM1 experiment. 
For the Decision Tree, two different implementations have been chosen for two 
different tests. 
The first implementation is bigML®, a commercial web service, that generates 
decision tree from datasets provided by the user. The bigML® implementation is 
based on CART decision trees but with modifications on the implementation in order 
to be able to deal with large volume data streaming based on algorithms by Tyree[60] 
and Ben-Haim[61], as explained by bigML® representatives, with whom I have been 
in contact in order to solve issues in their implementation that prevented the execution 
of the dataset. 
The test done has consisted on generating the decision trees for the six experiments in 
the study and see if the features used in the decision tree have any matching with the 
features extracted from the CM1 feature extraction. In this case, the ground truth 
provided consists on the classification of the patients on 4 types (C, A, O, GB). 
The second implementation is Python scikit-learn, that is based on an optimized 
version of the CART algorithm, no details are provided in the documentation. In this 
case, the samples provided where the clusters obtained as result from the study. The 





In order to study the dataset object of this work, a series of experiments have been 
executed. The design of the experiments corresponds to the different options described 
in the data pre-processing and normalization, namely: filter or not outliers, use sqrtJSD 
or Pearson distance and if sqrtJSD is used normalize by column or not. 










Normalization Column Row and 
Column 





No No No MAD>5 MAD>5 MAD>5 
Iterations 100 to 500 100 to 500 100 to 500 100 to 500 100 to 500 100 to 500 
Repetitions 100 100 100 100 100 100 












Table 10 Parameter Set Scenarios 
The workflow formerly described in the former section has been executed 100 times 
and the results obtained have been aggregated in order to evaluate the robustness of the 
method proposed. 
These experiments, as explained in E.2), have been limited due to limitations in 
computational resources. The time required for executing the complex networks 
method is very high, above 1 hour for each execution (for our parameters, as explained 
above). A total of more than 10 full days of execution are required to execute 100 
subsamples with the 6 different sets of parameters used. Then the rest of the processing 
(execution of the other clustering methods and consensus) is required. 
This limitation has been translated in two main aspects; first, only one dataset has been 
used in the study what does not permit to grant to the method any range of utility 
outside the current dataset.  
Second, because of the limitations regarding the execution of the clustering based on 
complex networks modularity, 100 executions have been made and those same have 
been used for the different iterations by choosing 80 to be combined. Despite this way 
of calculating, given the nature of the method, the repetitiveness of the method is not 
compromised for two reasons. First, the subsamples of the other methods are 
calculated independently and the method to choose the partitions to be combined is 
based on distances so our process is, in the worst case, equivalent to fix one of the 
parameters of the algorithm (one of the partitions). Second, this method is based on the 
56 
 
measure of modularity, and despite being calculated using stochastic methods, the 
results obtained are highly robust and therefore generating the subsamples for each 
iteration, instead of choosing among a set of generated ones, will not change the result. 
The membership coefficients obtained for the method confirm this reasoning, see 
Table 34. 
The number of iterations performed in the experiments has been in the range 100 to 
500 with increments of 100 iterations. Each experiment has been executed 100 times 
in order to measure the variability of the solutions obtained. 
In addition, the CM1 features selected have been compared with the ones used in two 
decision trees.  
Finally, the results have been analyzed by an expert on bio-markers in order to assess 
the relevance of the clusters found in addition to a quantitative analysis of the 





Figure 14, shows the final solution obtained for the RAW-JS settings, the only 
configuration that shows convergence in the result generated. With 200 iterations in 
the consensus generation, this configuration can produce a solution that is very 
consistent across multiple repetitions of the execution, Table 32 and Figure 25. Note 
that the clusters may be shown in different order. 
In Table 22,Table 23,Table 25,Table 26,Table 28,Table 29 and Table 32, the results 
for each of the configurations and different number of iterations is shown. In all cases, 
the result shown corresponds to the one with higher Purity as calculated for the study.  
In the case or RAW-JS, the method is converging at the higher Purity so this method is 
not biasing the result as we are analyzing the RAW-JS in parts of the analysis where 
this could be relevant. A different situation would have been if the convergence is not 
at the maximum Purity level, then the Median should have been taken, note that the 
Mean value may not correspond to any of the solutions generated. 
The different result partitions generate though different qualitative aspects and not all 
of them divide the dataset in the same way. Taking the case where N_Iterations=500, 
Table 28 and Table 29, the result for each setting produces the following partitions: 
 RAW WO-Outliers 
JS 1 Control group  (high Completeness) 
2 GB groups (high Homogeneity) 
1 Oligoblastoma group 
2 minor groups 
1 Control group 
2 GB groups (high Homogeneity) 
1 Oligoblastoma group 
1 minor group  
ROW-JS 1 Control group (high Completeness) 
2 GB groups (unbalanced) 
1 Oligoblastoma group 
2 minor groups 
1 control group (high Completeness) 
2 GB groups (high Homogeneity) 
1 Oligoblastoma 
1 minor group 
Pearson 1 Control group 
1 GB group (small with high 
homogeneity) 
1 GB group (large but with low 
Homogeneity) 
1 Oligoblastoma  group (small) 
2 small groups 
1 control group 
2 GB groups ( 1  high Homogeneity) 
1 Oligo (small, low Completeness, 
high Homogeneity) 
3 minor groups 
Table 11 Qualitative analysis of the best result for each configuration 
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Many of the results agree on the existence of two GB groups although there is 
disagreement about the relative size of them. The best result, higher Purity, as can be 
expected from the qualitative description, occurs for the WO Outliers-ROW JS, but 
this value is an outlier in the opposite direction to how the convergence seems to be 
occurring. The convergent RAW-JS generates the fourth best result across 
configurations, very tied with RAW-ROW JS and WO Outliers-JS. 
The number of iterations used in the algorithm is a sensitive parameter in order to 
obtain a consensus partition from the algorithm. In the explored ranged, from 100 to 
500, only the first settings have achieved absolute convergence and it can be 
considered that the method generates a unique result (and a bunch of outliers), see 
Figure 23 and Figure 24.  
An increase on the number of iterations only produces a noticeable improvement in the 
convergence of the results for some of the settings used Raw-JS and WO Outliers-
ROW JS. In a lesser degree, also for Raw-Pearson there is an increase on the 
convergence of the solution partition but not enough to consider the method generates 
a unique solution. 
The convergence is not only at the level of the final result but also at the individual 
clustering algorithms considered in the study. The Complex Networks modularity 
based method is by far the most stable method of the three used, with convergence at 
membership coefficient and partition generated. MSTKNN, generates the wider 
membership coefficient range, see Table 34. But the partitions generated show the 
same degree of convergence than Complex Networks, Table 39, and create the 
conditions for the method to converge: the two methods that generate the more 
different solutions converge separately for a number of iterations around 500. 
The changes introduced in the existing algorithms, weighting the partitions, have a 
positive impact on the stability of the partitions generated without biasing the results to 
the number of partitions that appears more often (MSTKNN), has a larger r range(CN 
modularity) or larger cophenetic distance difference (HC), see Table 6 and Figure 13 
as an example. 
About the effect of normalization, column normalization or row and column 
normalization, only the first has generated a convergent solution and this only for the 
complete dataset (including outliers). This may indicate that this extra normalization 
by row is getting rid of part of the discriminating information required to consensuate 
a partition. Jensen-Shannon is then measuring not only the expression level of genes 
among samples but the difference across samples and genes, first term in JSD, 
Equation 10. 
The fact that when the outliers are removed, the same convergence level is not 
achieved also indicates that the information on the outliers is required for the 
consensus and that despite the data distribution being wide this information is 
necessary. When the outliers are removed, the pairwise distances become more 
homogeneous and while the partitions obtained are still meaningful, the consensus is 
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not achieved. The redundancy in the Microarray Data is not enough to compensate for 
the aggressive removal of features. 
The Pearson correlation is not able to converge for none of the two datasets. This 
circumstance indicates that in order to measure the distance among samples is not only 
important the correlation among samples, as Pearson measures, but also the variation 
among genes in the samples and while Pearson considers σx of the distributions, the 
wide range of values in the gene expression matrix may not be able to properly 
represent it. JSD based on entropy, and using logarithms, is a better option. 
The decision of using the two more different individual algorithm solutions, is not 
biasing the result as for different settings, the pair that receives the more votes is 
different, example Table 8. MSTKNN is always one of the algorithms involved. 
 
Figure 15 Consensus partition result for RAW-JS settings 
The main question to be answered is how the consensus can be reached when one of 
the two components (MSTKNN) has such important variability, in the membership 
coefficient.  
To verify that, analogously to how the final solution robustness has been assessed, the 
solutions generated for each of the methods have been compared pairwise,  Table 39, 
there it can be observed that for Complex Networks algorithm and MSTKNN, for 500 
iterations in the consensus, there is absolute convergence of the solution generated. 
This does not happen for Hierarchical Clustering that maintains high variability, as 
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could be expected from the comments in IV.C.1)c) Disadvantages of Hierarchical 
Clustering. For the WO Outliers-Row JS configuration, the second closer to 
convergence, only the CN algorithm converges, Table 40. 
The reason then for the high variability of the membership coefficient comes, because 
of the weighting system, not only from the variability of the consensus matrix that will 
become the individual solution, best K, also the other consensus matrixes have an 
influence as the weights change. To confirm this, we need to check how the best K is 
changing, what can be seen in Table 38; it can be observed that the best K, for Raw JS, 
is always the same, k=3. This happens even when the curves for different executions is 
very variable. It can also be observed that this is not the case for other configurations 
than RAW-JS for MSTKNN.  
About the comparison of the selected features with the CM1 indicators, for the 
experiment using bigML, there has not been any match for any of the 165 unique 
probes, 1-vs-all, with the features used by bigML. It has been observed that many of 
the features in the bigML decision trees are used several times in the same tree. The 
tree has 40 internal nodes and the same feature is used up to 8 times in the tree, only 3 
features are used only once. In this case, using the same feature many times can 
explain that there is no coincidence as the partitions are done in a more precise way. 
Also in DT, the selection of features is done at every level.  
In the case of scikit-learn only one out of seven features, 212187_x_at (PTGDS), has 
appeared in the CM1 features extracted from the study. In this case, none of the 
features is repeated in the Decision Tree.  What is interesting is that the gene appears 
in the G1X vs G2X group, down-regulated in second position, and G1X, down-
regulated in  second position, and in the Decision Tree it separates precisely the G1X 






















Figure 16 Probesets and genes used in Scikit Decision Tree for the cluster separation 
 
Figure 17 Scikit Decision Tree applied to the cluster solution  
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IX. DISCUSSION AND CONCLUSIONS 
Based on the primary solution, the one with greatest convergence, Raw-JS, two groups 
with 33 and 29 samples have been partitioned, with only 15 samples being assigned to 
other clusters and 8 and 11 samples respectively being included in the groups with a 
different diagnose. The control group (C), the only one that can be granted absolute 
reliability, has been clearly partitioned although the group includes 27 other samples 
that are not controls, what is a downside of the solution. The Oligoblastoma group(O) 
has also been identified, with 32 out of 50 samples in a majoritarian group where only 
11 samples do not share this diagnosis. The Astrocytoma group has not been clustered 
what is according to the low consensus ratio for the diagnose of this tumor subtype and 
its smaller representation in the dataset. 
Based on the results obtained it becomes tempting to try to classify the Unclassified 
samples in the dataset based on the cluster they belong in the solution partition, and the 
majoritarian class on it. If that could be accepted, three out of the four unclassified 
would correspond to GB subtype, what considering that GB is the most reliably 
classified subtype (see Appendix XI.G) seems unlikely, but possible. The fourth 
subtype would be a Control sample what is unlikely to appear as unclassified. As 
stated in [19], this classification process would be biased and what is required is to 
apply supervised learning techniques that based on the clusters obtained select, without 
the Unclassified samples, the discriminant features and then the classification could be 
performed. 
The statistical relevance of the results has been evaluated using two different methods. 
The first, internal, is based on the similarity of the results obtained when the 
experiments have been repeated several times and complemented by the measurement 
of the variation of the membership coefficients of the consensus matrixes of each of 
the clustering methods. The fact that robustness of the solution has been verified using 
internal methods is a solid indicator of the robustness of the result, as stated in [19]. 
The tables in section XI.B showing the Agreements and Indexes and Metrics witness 
this circumstance that is notably visible in Table 30, Table 31 and Figure 24 as well as 
Figure 25, Table 33 and Table 34. 
The second, external, measures the variability of the intra- and extra- Purity metrics 
designed to consider the discovery of new classes. Both of them show highly 
consistent behavior in all 6 cases and (almost) absolute convergence for the Raw-JS 
settings, see Figure 23 and Table 35.  
The value is around 1.43 (bounded 0-2), what is in the range of accuracy that 
physicians have in the best case, 70%, see Appendix XI.G, while the comparison is not 
strict as the measures used are different although strongly related. This level of 
accuracy is also in the same interval that other studies that have used the same dataset 
obtaining accuracies in the range of 40% to 72% depending on how the dataset is used 
(training or test), see XI.H Known results obtained from dataset GSE4290. 
For the RAW-JS solution, the relevance of the genes discriminating found via CM1, 
have been validated by an expert on biomarkers. The detailed results can be read on 
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Appendix XI.A. The link to carcinogenic process is manifest as it is the number of 
publications that relate these genes to brain tumors. The results confirm the existence 
of Glioblastoma subtypes that the literature claims, see XI.A.2) for an expert validation 
of the results.  
Verifying the statistical significance of the discovered genes, what is a common 
practice in the literature, as stated in [19],  cannot be made based on conventional 
statistical tests, as the tests assume independence of the class definition and 
expression-profile data, what is not the case for cluster defined classes. 
The lack of coincidence when trying to match the results to the features used in 
decision trees, gives support to [19], when claims that the classification of the 
unknown samples cannot be done based on the clustering results and a supervised 
method is required. 
Also based on the Qualitative Analysis we find that from the 194 unique genes 
considered relevant for the study 119 genes are directly associated with Cancer and 
nervous diseases, what represents 61.3%. The number of unique genes is also an 
important factor to consider, as detailed in Appendix XI.C.1).  
From a total theoretical of 453 after removing the probesets not in the SOURCE 
database, and counting only once the G1X-vs-G2X and its complementary, only 194 
genes have remained what make for a very compact set that also adds, because of the 
many-to-1 association, another indicator of robustness of the solution. 
The robustness happens also for each of the CM1 classes identified as can be seen in 
Table 49, where the number of unique genes consolidating by class (no coincidence of 
probeset since CM1 index is unique per each feature) is 417 out of 553. 
In addition, the 19 out  of 160 genes also found in other GSE4290 studies, are another 
proof of the interest of the method, as the low percentage cannot bring us to 
underestimate the result given the diversity of the studies considered, their techniques 
and their low mutual agreement (only 5 genes appear more than once), see Appendix 
XI.H. 
Overall, the current study has contributed a method in order to extract a consensus 
clustering even when different algorithms have very divergent views of the dataset. 
The existing algorithms in the literature ignore some of the problems unveiled as part 
of the research. The proposed methodology can be adapted by using different 





X. FUTURE WORK 
The results obtained are promising in order to continue working on the evolution of the 
methodology proposed. Obvious evolutions would be to include other clustering 
methods, and specifically methods that are based on the whole feature space, as the 
more different ones from the ones already considered. 
A comparison of the effect of the weights assigned to the different partitions would 
help to understand the main source of variability in the method and come out with new 
weighting parameters that can guarantee the convergence for different clustering 
algorithms or indicate that the lack of convergence shows the algorithm is not able to 
partition the dataset robustly. 
The main question open by the study is how the clustering would be affected if the 
CM1 genes selected, both 1-vs-all and 1-vs-1, would be used as feature selection and 
the process re-run for the subset of probesets. The hypothesis to confirm is that the 
clusters will become stronger, requiring less iterations to reach strong consensus, but 
also that the results will improve as measuring only the relevant genes will get rid of 
the noise introduced by the indiscriminant genes (that are 2 orders of magnitude more 
numerous) producing a more reliable result. This process could be repeated iteratively 
until a certain stability criterion is met. This process corresponds to the red arrow in 
Figure 6. 
The dataset used in the study is a quite large one, if compared to other Microarray Data 
studies, the effect of the size of the dataset should be considered and datasets with less 
samples be tested. 
The new defined intra-/extra-Purity measure should be further evaluated in order to 
compensate for the biases already detected and explained in its definition. 
Additionally, it could be modified in order to be able to manage better cases where the 
size of the different classes is unbalanced. A first approach in this direction would be 
to consider the relative number of elements of each class instead of its absolute 
number. 
This measure could also be improved if the membership coefficient in the solution 
partition for each of the samples is considered, instead of a 0/1, as it is the case now, 
that would connect our method with existing clustering methods based on fuzzy logic 
as well as Bayesian methods like Block Model [62] that when evaluated have 
produced quite interesting results in almost real time and where a better data 
modelling, to satisfy data distribution requirements for the method, could improve the 
overall results. 
 
Table 12 Block model clustering confusion matrix 
0 1 2 3 4
Control 1 1 0 0 19 3 23
Glio 2 2 4 62 4 5 77
Unknown 7 0 1 2 1 0 4
10 7 96 33 34
14 3 6










A. Bio-interpretation of the results 
1) Qualitative evidence of relevance 
For the lists of genes obtained, Table 47 and Table 48, its relationship to Cancer 
processes has been assessed. In order to do that, the genes have been queried against 
the database CTD (Comparative Toxicogenomics Database) and the Curated Disease 
Associations extracted: http://ctdbase.org/tools/batchQuery.go. All the associations 
obtained are made based on PubMed publications. 
Based on that, the following conclusions have been extracted. The 8 genes on Table 14 
correspond to genes that in CTD appear linked to varieties of Epilepsy (our control 
group is made up of Epilepsy patients). But only 2 of the genes (STXBP1 and 
SLC1A2) are found in the CX-vs-all CM1 selection. This happens because genes are 
usually involved in many biological processes. Also the information provided doesn’t 
consider the degree of participation on the diseases so the results in this part must be 
considered as weak evidence. 
Table 15 contains the 18 genes related directly to a variety of different tumor types 
(glioma, glioblastoma, gliosarcoma, astrocytoma, oligodendroglioma, lymphoma, 
neuroblastoma). Only 2 of the genes in the Epilepsy list (NTRK2, VEGFA) appear in 
this list. 
Table 16 contains the 89 genes related to any kind of Cancer disease. Only 4 of the 
genes in the Epilepsy list appear in this list (NTRK2, VEGFA, SLC1A2, GAP43). 
Since the tissue being studied is brain tissue and the technique used is based on mRNA 
and therefore active genes, the gene can be considered related to the brain tumor. 
Table 17 contains the 119 genes that the database associates with any kind of cancer 
plus nervous diseases, as advanced states of the disease cause other nervous problems 
to appear. 
In addition to this, the KEGG database can be used to analyze the relationships among 
genes from different perspectives. This analysis requires a deeper understanding of the 
medical implications in order to be properly evaluated and can only be properly made 
by an expert in the topic. 
Finally, comparing the genes identified in the study with others that have been 
considered relevant in studies that have also used the GSE4290 dataset, see Appendix 
H, we find that we have identified 19 out of 160 unique genes. This percentage 
although can be considered low, is not so low, as in the studies only 5 genes appear in 
more than one study. Also, some of the studies combine information from different 
datasets and the GSE4290 is used as test set and in other cases the studies are based 





MBP OLIG2 ID4 
PLP1 VCAN EGR1 
BASP1 SOX8 APOD 
EGFR IGFBP2 GSN 
PTN CHI3L1 ANXA1 
PTPRZ1 TIMP1 CD99 
ENPP2     
Table 13 Genes also found in other GSE4290 studies 
SPARCL1 Downregulated in G1X-vs-all NES Appears in G1X-vs-G2X 
STXBP1 Upregulated in CX-vs-All NTRK2 Downregulated in G1X 
Upregulated in OX 
Appears in G1X-vs-G2X 
SLC1A2 Upregulated in CX-vs-All GRIA2 Downregulated in G1X 
VEGFA Upregulated in G1X and G2X-vs-All.  
Downregulated in OX-vs-All 
GAP43 Downregulated in OX 
Table 14 Genes related to Epilepsy 
FAM107A FTH1 SOD2 
NTRK2 HLA-C HLA-DRB1 
CHI3L1 HLA-B HEY1 
SPP1 HLA-A GNAS 
FN1 EGFR JAG1 
VEGFA B2M APOD 
Table 15 Genes related to Glioma, Glioblastoma, Gliosarcoma, Astrocytoma, Oligodendroglioma, Limphoma, 
Neuroblastoma 
FAM107A CST3 CD44 CHI3L1 B2M PEG3 
TF S100A6 CTSB SERPINA3 GNB2L1 GNAS 
BASP1 IGFBP5 HLA-DRB1 SPP1 EEF1A1 VOPP1 
NTRK2 LGALS3 CD74 VIM IGFBP7 HSPA8 
NDRG2 ANXA1 RPL3 FABP7 CD99 PPIA 
CRYAB MAOB PABPC1 IGFBP2 ACTG1 DBI 
SCD UCHL1 ZBTB20 LGALS1 MT2A EGR1 
OLFM1 HLA-C MARCKS FN1 POSTN COL6A1 
SLC1A2 MT3 VCAN VEGFA IGFBP3 MALAT1 
ATP1B1 HLA-B ID4 FTL PTN JAG1 
EEF1A2 HLA-A RPS3 FABP5 AQP1 TRIO 
TSC22D1 RPS19 RPS6 CD63 LTF APOD 
FXYD6 RPL13 APOE GAP43 A2M GSN 
TUBB2A SPARC HEY1 FTH1 CLU SEPP1 
PTPRO EGFR PRKACB PGK1 SOD2   





MBP MT3 NPTN MARCKS OLFM1 POSTN FABP5 HSPA8 
PLP1 HLA-B TUBB2A VCAN ADD3 IGFBP3 CD63 NES 
FAM107A HLA-A PTPRO ID4 QDPR PTN GAP43 PPIA 
RTN1 RPS19 CHI3L1 RPS3 SPARCL1 AQP1 FTH1 DBI 
TF RPL13 LDHA RPS6 SLC1A2 LTF PGK1 EGR1 
SNAP25 SPARC SERPINA3 APOE TSPAN7 A2M COL1A1 COL6A1 
BASP1 EGFR SPP1 HEY1 SOX8 CLU CST3 MALAT1 
NTRK2 B2M VIM PRKACB CALM1 SOD2 S100A6 JAG1 
CHN1 GNB2L1 FABP7 PEG3 ATP1B1 CD44 IGFBP5 TRIO 
NDRG2 EEF1A1 TIMP1 IDS GABBR1 CTSB LGALS3 APOD 
CRYAB IGFBP7 IGFBP2 SLC17A7 NEFL HLA-DRB1 ANXA1 GSN 
KIF5C CD99 LGALS1 YWHAH SYN2 CD74 COL4A1 CD24 
SCD RPL27A FN1 SERPINI1 EEF1A2 RPL3 MAOB PSAP 
STXBP1 ACTG1 VEGFA GNAS TSC22D1 PABPC1 UCHL1 SEPP1 
GRIA2 MT2A FTL VOPP1 FXYD6 ZBTB20 HLA-C   
Table 17 Genes related to Cancer and Nervous System Disease 
 
2) Expert evaluation: a bio perspective (by Prof. Pablo Moscato) 
Based on the CM1 features for the 4 1-vs-all separations and the G1X-vs-G2X and 
G2X-vs-G1X, Prof. Pablo Moscato, Co-Director of the Centre for Bioinformatics, 
Biomarker Discovery and Information-based Medicine at the Hunter Medical Research 
Institute (Newcastle, NSW, Australia), has analyzed the results. What follows in this 
subsection XI.A.2), is his analysis of the results applying its knowledge in the field of 
bioinformatics and cancer research. His collaboration has been independent of the rest 
of the study. 
The bibliographical references in this section, numerous as they are, close to 200, 
are included in a separated References section: References for bio-informatics 
study. 
 
a) Preliminary analysis 
Figure 18 shows the Venn Diagram analysis of CM1 positive genes, upper-expressed, 
in the comparisons between G1-vs-all (G1X), G2-vs-all(G2X), O-vs-all(OX) and C-
vs-all(CX). We have only used the probesets that have a positive value of CM1. For 
each set, we listed gene names to which probes have been mapped and also the 
probe sets names. This naturally explains why we have 91 objects in CX, which 
correspond to the 50 associated probe sets with the highest values of CM1 scores as 




The first observation is that, in general, there is no intersection between the sets, with 
the single exception of 39 markers that are in the intersection of G1X and G2X. In this 
intersection subset we found several markers which are common in glioblastoma. The 
list contains the following genes:  
 SPP1 (Secreted Phosphoprotein 1, Osteopontin), 
 CHI3L1 (chitinase 3-like 1 (cartilage glycoprotein-39),  
 VIM (Vimentin),  
 FN1 (Fibronectin 1),  
 VEGFA(vascular endothelial growth factor A),  
 HLA-A (major histocompatibility complex, class I, A),  
 HLA-B (major histocompatibility complex, class I, B),  
 HLA-C (major histocompatibility complex, class I, C),  
 TIMP1 (TIMP metallopeptidase inhibitor 1),  
 MT2A (metallothionein 2A),  
 LGALS1 (lectin, galactoside-binding, soluble, 1),  
 TMSB10 (thymosin beta 10),  
 IGFBP7 (insulin-like growth factor binding protein 7),  
 B2M (beta-2-microglobulin) 
 CD63 (CD63 molecule) 
A probe corresponding to 234989_at could not be mapped to a known gene.  
There are also probesets that differentiate the group G1 from the rest. They total 39. 
They correspond to the following genes:  
 EGFR (epidermal growth factor receptor),  
 FABP7 (fatty acid binding protein 7, brain), 
 SEC61G (Sec61 gamma subunit), 
 PTN (pleiotrophin), 
 LDHA (lactate dehydrogenase A), 
 IGFBP2 (insulin-like growth factor binding protein 2, 36kDa) 
 IGFBP3 (insulin-like growth factor binding protein 3), 
 COL4A1 (collagen, type IV, alpha 1),  
 ACTG1 (actin, gamma 1), 
 POSTN (periostin, osteoblast specific factor),  
 LGALS3 (lectin, galactoside-binding, soluble, 3), 
 RPS19 (ribosomal protein S19) 
 RPS2 (ribosomal protein S2)  
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The following probe sets, which are also in this group, are not mapped to a gene 
(232541_at, 216438_s_at). 
 
Figure 18 Probesets and genes from 1-vs-all CM1 
The third group to discuss is the 47 probesets that correspond to G2X which are not in 
the other subsets. The genes associated to these probesets are: 
 SERPINA3 (serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3),  
 C3 (complement component 3),  
 FTL (ferritin, light polypeptide),  
 FTH1 (ferritin, heavy polypeptide 1),  
 LTF (lactotransferrin),  
 CD74 (CD74 molecule, major histocompatibility complex, class II invariant 
chain), HLA-DRB1 (major histocompatibility complex, class II, DR beta 1),  
 HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1),  
 CD44 (CD44 molecule (Indian blood group),  
 SOD2 (superoxide dismutase 2, mitochondrial),  
 CLU (Clusterin),  
 A2M (alpha-2-macroglobulin),  
 COL1A1 (collagen, type I, alpha 1),  
 S100A6 (S100 calcium binding protein A6),  
 C1QC (complement component 1, q subcomponent, C chain),  
 CTSB (cathepsin B),  
 MAOB (monoamine oxidase B),  
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 LAPTM5 (lysosomal protein transmembrane 5),  
 AQP1 (Aquaporin 1),  
 ANXA1 (annexin A1), 
 IGFBP5 (insulin-like growth factor binding protein 5) 
Many of the 50 probesets in CX correspond to neuron markers like: 
 VSNL1 (visinin-like 1),  
 RGS4 (regulator of G-protein signaling 4),  
 SNAP25 (synaptosomal-associated protein, 25kDa),  
 NEFL (neurofilament, light polypeptide), etc.,  
or oligodendrocyte specific markers like:  
 MBP (myelin basic protein),  
 PLP1 (proteolipid protein 1), etc  
The increased value of CM1 in this group is clear as the comparison of the tumors 
against the controls indicate that there is a process of dedifferentiation from the brain 
architecture tissue and these neuron and oligodendrocyte specific markers are less 
abundant due to large majority of tumor cells in the samples. This said, we will 
concentrate our attention to the following three groups. 
 
Figure 19 Venn-diagram for G1X-vs-G2X, OX, CX 
We then proceed to calculate a signature of the top 100 probesets that best separate, 
according to the CM1 score, the group of samples labelled G1 from those labelled G2. 
As the CM1 score is not symmetric we calculated CM1 scores for all probes in two 
opportunities, i.e. having each of the two groups as the group of interest. However, in 
this case both results gave the same set of top positive and negative first 50 probesets. 
We call this group of probesets and the associated mapped genes as `G1X-vs-G2X’ 
(see Figure 19). We compare this set with those that have appeared in the list for OX 
(that differentiate this group from the rest of samples) and also those that are in the 
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group CX. We observe that there is a small intersection in the first case, five probesets 
(221796_at, 221795_at, 209283_at, 203381_s_at, 203382_s_at) mapping to the genes: 
 NTRK2 (neurotrophic tyrosine kinase, receptor, type 2),  
 CRYAB (crystallin, alpha B)  
 APOE (apolipoprotein E)  
In the second case we have matches, corresponding to the probesets: 209072_at, 
211748_x_at, 210198_s_at, 212187_x_at, 207323_s_at, 227556_at, 209123_at, 
201242_s_at, with matches to well-known oligodendrocyte markers: 
 MBP (Myelin Basic Protein) [1] 
 PLP1 (Proteolipid Protein 1/ Myelin proteolipid protein) [1] 
 PTGDS (prostaglandin D2 synthase 21kDa (brain))  
 NME7 (non-metastatic cells 7, protein expressed in (nucleoside-diphosphate 
kinase)), 
 QDPR (quinoid dihydropteridine reductase)  
 ATP1B1 (ATPase, Na+/K+ transporting, beta 1 polypeptide) 
This relatively small intersection indicates that the differences between the groups G1 
and G2 are, its top CM1 scoring, when computed independently of any other type of 
sample, very different to those of CX and OX as previously obtained. 
 
Figure 20 G1X and G2X Venn diagram analysis 
With this information, we proceeded to compute another diagram, Figure 20. We 
include again this group of 100 probesets and their mapped genes and we label them as 
`G1-vs-G2’. We compare this lists with those of the intersection of the groups G1X 
and G2X (now labelled G1X-int-G2X) and the group obtained from G1X but 
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eliminating the markers in G2X (labelled G1X/G2X) and those in G2X but eliminating 
the markers in G1X (analogously labelled [2, 3]).  
In this case we are interested in some intersections.  The intersection of G1-vs-G2 and 
G1X-int-G2X only brings as a marker probeset 201426_s_at, for VIM (Vimentin). 
This is an important finding that will be discussed later. The intersection of G1-vs-G2 
and G1X/G2X brings the probesets 216438_s_at, 210095_s_at, 200869_at, 
208949_s_at, 210809_s_at, 205029_s_at, 201984_s_at, 202718_at, 211737_x_at, [4, 
5], 205030_at, 224999_at, 201983_s_at, corresponding to the genes: RPS2, IGFBP3, 
LGALS3, EGFR, POSTN, FABP7, IGFBP2, PTN, SEC61G.  
The intersection between G1-vs-G2 and G2X/G1X is smaller with 200748_s_at, 
202376_at, 217767_at, 213187_x_at, 212788_x_at, 200839_s_at, 201721_s_at, 
225353_s_at corresponding to the genes: FTH1, SERPINA3, C3, FTL, CTSB, 
LAPTM5, C1QC. 
b) Annotation of the results 
In Figure 18 we pointed to the existence of several genes in both G1X and G2X that 
have the top CM1 scores. Since G1 and G2 are clusters that contain many samples 
labelled as glioblastoma, it is important to correlate the result with the literature. We 
start with the genes found in the intersection. The list includes: 
Gene Name and synonyms References 
SPP1 Secreted Phosphoprotein 1, Osteopontin 14: [6-19] 
CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) (Synonims 39 kDa 
synovial protein, ASRT7, Cartilage glycoprotein 39, CGP-39, 
Chitinase-3-like protein 1, DKFZp686N19119, FLJ38139, GP39, 
GP-39, hCGP-39, HC-gp39, HCGP-3P, YKL40, YKL-40, YYL-
40 ) 
36: [6, 11, 20-53] 
VIM Vimentin 11: [23, 50-59] 
FN1 Fibronectin 1 25: [11-13, 60-81] 
VEGFA Vascular endothelial growth factor A 6: [3, 5, 82-85],   
TIMP1 TIMP metallopeptidase inhibitor 1 11: [14, 88-97] 
MT2A metallothionein 2A 1:[98] 
HLA-A major histocompatibility complex, class I, A 2: [86, 87] 
CD63 CD63 molecule 1: [13] 
HLA-B major histocompatibility complex, class I, B Related to HLA-A 
HLA-C major histocompatibility complex, class I, C Related to HLA-A 
LGALS1 lectin, galactoside-binding, soluble, 1  Related to LGALS3 
TMSB10 thymosin beta 10  
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IGFBP7 insulin-like growth factor binding protein 7 Related to IGFBP2 
B2M beta-2-microglobulin  
Table 18 Genes common to G1X and G2X, literature references 
We now turn our attention to the probesets that differentiate the group G1 from the 
rest. They correspond to the genes in Table 19. 
Gene Name and synonyms References 
EGFR epidermal growth factor receptor 19: [86, 99-116] 
FABP7 fatty acid binding protein 7, brain 8: [117-124] 
SEC61G Sec61 gamma subunit 2:[86, 125] 
PTN pleiotrophin 12:[4, 5, 115, 126-134] 
IGFBP3 insulin-like growth factor binding protein 3 13:[5, 135-146] 
COL4A1 collagen, type IV, alpha 1 1:[116] 
ACTG1 actin, gamma 1 1:[147] 
POSTN periostin, osteoblast specific factor 3:[16, 148, 149] 
RPS2 ribosomal protein S2 2:[150, 151] 
LGALS3 lectin, galactoside-binding, soluble, 3 See below 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa See below 
RPS19 ribosomal protein S19  
LDHA lactate dehydrogenase A  
Table 19 Genes only in G1X 
The following probe sets, which are also in this group, are not mapped to a gene 
(232541_at, 216438_s_at). 
The intersection of G1-vs-G2 and G1X/G2X brings the genes in Table 20. 
Gene Name and synonyms References 
EGFR epidermal growth factor receptor 13:[4, 5, 115, 126-134] 
POSTN periostin, osteoblast specific factor 3:[16, 148, 149] 
FABP7 fatty acid binding protein 7, brain 8:[117-124] 
IGFBP3 insulin-like growth factor binding protein 3 13:[5, 135-146], 
PTN  pleiotrophin 13:[4, 5, 115, 126-134], 
SEC61G  Sec61 gamma subunit 2: [86, 125] 
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LGALS3 lectin, galactoside-binding, soluble, 1 See below 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa See below 
Table 20 Genes G1-vs-G2 and G1X/G2X 
The intersection between G1-vs-G2 and G2X/G1X contains the genes in Table 21. 
Gene Name and synonyms References 
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 2: [9, 152] 
FTL ferritin, light polypeptide 3: [153-155] 
CTSB Cathepsin B/APP secretase 20: [156-175] 
LAPTM5 lysosomal protein transmembrane 5 1:[176] 
FTH1 Ferritin, Heavy polypeptide 1/Cell proliferation-inducing gene 15 protein  
C3 Complement Component 3  
C1QC complement component 1, q subcomponent, C chain  
 Table 21 Genes G1-vs-G2 and G2X/G1X 
c) Conclusions 
Overall, the number of genes that are presented in Tables 18, 19 and 20 that are related 
to glioblastoma is really impressive. It does seem to be that there are differences 
related to the expression of EGFR, IGFBP3 and PTN (to mention three which have 
been widely studied) while the method also brings to the attention IGFBP2 (from the 
same family) and LGALS3 (also known as Galectin-3) it has been proposed as a 
marker that can distinguish pilocytic astrocytomas from diffuse astrocytomas, and 
glioblastomas from anaplastic oligodendrogliomas in [177]. These results indicate that 
perhaps it should be consider as a marker to be used in relationship with the others in 
these panels. In [78], the authors analyzed 409 cases of surgically resected primary 
brain tumors and found its expression to be “definitely positive but heterogeneous” in 
glioblastoma and other types of tumors. This is coherent with the observation here, 
which seems to indicate that LGALS3 may co-express with EGFR, IGFBP3 and 
PTN in one subtype of glioblastoma. We refer to other papers on this gene for further 
references on reports on this gene in relationship with glioblastoma 
[177,178,179,180,181,182,183,184,185,186,187,188,189]. Plasma IGFB2 levels seem 
to correlate with prognosis of glioma patients [190] and anaplastic astrocytomas [191]. 
Immunohistochemistry for this gene was positive in 88.8% of the cases in a study 
involving 28 glioblastomas [192]. Several other studies have also linked it to cell 
proliferation and migration [193] and it deserves also to be included in the studies of 





B. Experiments results 
This section contains all the graphs corresponding to the different experiments run for 
the study. 
1) All methods, N Iterations=100 



































































Table 22 Partition results for N Iterations=100, Raw Dataset 
 











































































































Figure 21 Accuracy for N Iterations=100 
2) All settings, N Iterations=200 








































































































































Table 26 Partition results for N Iterations=200, WO Outliers 
 




































Figure 22 Accuracy for N Iterations=200 
 
3) All settings, N Iterations=500 








































































































































Table 29 Partition results for N Iterations=500, WO Outliers 
 

















Table 30 Indexes for N Iterations=500 




















Figure 23 Accuracy for best partition N Iterations=500 
 




4) Raw, Column-Normalization, Jensen-Shannon, N Iterations=100 to 400 
































Figure 25 Accuracy for different Nr of Iterations for Raw Jensen-Shannon settings 















5) Comparison of Accuracy for all methods 











6) Selection of Best K 
In order to show the variability of the Best K for each algorithm 10 executions have 
been performed and the AUC and best K plotted for each of them. The thickness of the 
vertical lines is proportional to the number of times the K has been the one with best 
AUC improvement. In some occasions the area for K=2 is not represented as it 
corresponds to ∞ an increase of as it compares to 0. The evolution of the AUC for 




































































































































































































7) Solution variability for each algorithm for RAW-JS configuration 
 CN HC MSTKNN 
100 
   
200 
   
500 
   
Table 39 Variability of the solutions for individual algorithms in RAW-JS configuration 
8) Solution variability for each algorithm for WO Outliers-JS 
 CN HC MSTKNN 
500 
   




C. Feature selection using CM1 
1) Probeset to Gene matching from CM1 extracted features 
Table 44, Table 45 and Table 46 show the list of features obtained from the CM1 
indicator for the main scenarios in the study, 1-VS-all for all the classes and 1-vs-1 for 
the two Glioblastoma types detected, over-expressed (green), under-expressed(red). 
The initial list of 100 probesets for case (50 over-expressed, 50 under-expressed) has 
been mapped to their corresponding genes using the SOURCE public database in a 
many-to-1 process (more than one probeset correspond to the same gene):  
http://smd.princeton.edu/cgi-bin/source/sourceBatchSearch 
From the whole list of probesets shown in the aforementioned tables, only 26 unique 




























Table 41 Probes IDs not found on SOURCE database 
If the found genes are consolidated to eliminate duplicate assignments, we obtain the 
lists of genes in Table 47 and Table 48, where the name in brackets shows the number 
of genes in the column, respectively for up-regulated and down-regulated.  
It is also relevant to mention that despite CM1 not being a symmetric indicator, the 
Genes obtained for G1X-vs-G2X up-regulated match completely the G2X-vs-G1X 
down-regulated and vice versa, columns 5 and 6, compared crossway, in Table 47 and 
Table 48. Table 49 summarizes the number of unique genes per class, no duplication 
of probesets since CM1 score is unique for each probeset and also the “Not found” 
probesets for each class. The low total indicates high coherence of the results. 
If all the genes for 1-vs-all are consolidated, a total of 165 genes are obtained, Table 
42, the G1X-vs-G2X contribute 29 additional unique genes, Table 43, up to 194 genes. 
The maximum theoretical is 453, so it represents a ratio of appearance of 2.33 times 



















Table 43 Unique Gene IDs in G1X-vs-G2X, G2X-vs-G1X not in 1-VS-all 
 
MBP NDRG2 MLLT11 SYN2 PTPRO VEGFA YWHAG GNB2L1 IGFBP3 RPL34 OLIG2
PTGDS CRYAB SPARCL1 GPM6A NGFRAP1 FTL MAOB RPL13A PTN RPS3A SCD5
PLP1 KIF5C FAM123A EEF1A2 AK5 FABP5 UCHL1 RPLP2 AQP1 RPL7 SMOC1
FAM107A NRGN SLC1A2 TSC22D1 CHI3L1 CD63 HLA-C RPL39 LAPTM5 RPL3 LRIG1
RTN1 SCD TSPAN7 GABBR2 TMSB10 GAP43 MT3 RPS16 LTF PABPC1 BCAN
FBXL16 STXBP1 SOX8 RGS4 LDHA FTH1 HLA-B EEF1A1 A2M ZBTB20 C1orf61
TF GRIA2 CAMK2N1 MAP2 SERPINA3 PGK1 HLA-A RPS15A CLU MARCKS OLIG1
SNAP25 OLFM1 RTN3 FXYD6 SPP1 COL1A1 RPLP0 IGFBP7 HLA-DPA1 VCAN NME7
BASP1 MAP1A CALM1 NAPB VIM CST3 RPS2 RPS11 SOD2 ID4 PRKACB
SYT1 ADD3 ATP1B1 DNM1 FABP7 S100A6 RPS19 RPLP1 CD44 RPS3 PEG3
NTRK2 C7orf41 PEA15 NPTN TIMP1 IGFBP5 RPL13 CD99 CTSB RPS6 IDS
ALDOC QDPR GABBR1 TUBB2A IGFBP2 LGALS3 SPARC RPL27A C1QC TCF12 SLC17A7
VSNL1 EDIL3 BEX1 NDRG4 LGALS1 ANXA1 PTPRZ1 ACTG1 HLA-DRB1 APOE MDH1
PLEKHB1 GPRC5B NEFL AGXT2L1 SEC61G ACTN1 EGFR MT2A CD74 HEY1 YWHAH
CHN1 STMN2 ENC1 CPE FN1 COL4A1 B2M POSTN C3 RPL30 SERPINI1
TRIB2 HSPA8 LANCL2 COL6A1 APOD PFN2 ENPP2 SEPP1
GNAS NES EGR1 MALAT1 GSN DNER RNASE1
VOPP1 PPIA S100A16 JAG1 SLC44A1 CD24 CLDN11




Table 44 CM1 Underexpressed genes, 1-VS-ALL 
PROBE ID GENE SYMBOL PROBE ID GENE SYMBOL PROBE ID GENE SYMBOL PROBE ID GENE SYMBOL
209072_at MBP 203485_at RTN1 209395_at CHI3L1 201426_s_at VIM
211748_x_at PTGDS 203999_at SYT1 217733_s_at TMSB10 211720_x_at RPLP0
210198_s_at PLP1 203797_at VSNL1 209396_s_at CHI3L1 208856_x_at RPLP0
212187_x_at PTGDS 202507_s_at SNAP25 200650_s_at LDHA 201033_x_at RPLP0
207323_s_at MBP 227641_at FBXL16 202376_at SERPINA3 212433_x_at RPS2
209074_s_at FAM107A 210222_s_at RTN1 209875_s_at SPP1 213414_s_at RPS19
203485_at RTN1 204081_at NRGN 201426_s_at VIM 203107_x_at RPS2
227641_at FBXL16 211985_s_at CALM1 205030_at FABP7 221798_x_at not found
203400_s_at TF 225491_at SLC1A2 201666_at TIMP1 214351_x_at RPL13
202508_s_at SNAP25 212624_s_at CHN1 234989_at not found 200665_s_at SPARC
202391_at BASP1 202508_s_at SNAP25 202718_at IGFBP2 211972_x_at RPLP0
203999_at SYT1 202022_at ALDOC 216438_s_at not found 202649_x_at RPS19
221796_at NTRK2 202391_at BASP1 201105_at LGALS1 215313_x_at HLA-A
202022_at ALDOC 203146_s_at GABBR1 203484_at SEC61G 209395_at CHI3L1
203797_at VSNL1 202260_s_at STXBP1 211719_x_at FN1 204469_at PTPRZ1
209504_s_at PLEKHB1 218332_at BEX1 216442_x_at FN1 209396_s_at CHI3L1
221795_at NTRK2 205591_at OLFM1 210512_s_at VEGFA 201983_s_at EGFR
212624_s_at CHN1 221805_at NEFL 204141_at TUBB2A 216231_s_at B2M
202507_s_at SNAP25 211984_at CALM1 210495_x_at FN1 202376_at SERPINA3
206453_s_at NDRG2 202242_at TSPAN7 218309_at CAMK2N1 200869_at not found
209283_at CRYAB 203000_at STMN2 213187_x_at FTL 200651_at GNB2L1
203130_s_at KIF5C 201341_at ENC1 202345_s_at FABP5 210646_x_at RPL13A
214063_s_at TF 229039_at SYN2 200663_at CD63 200909_s_at RPLP2
204081_at NRGN 219549_s_at RTN3 212464_s_at FN1 213932_x_at HLA-A
200832_s_at SCD 209469_at GPM6A 204471_at GAP43 208695_s_at RPL39
202260_s_at STXBP1 201522_x_at not found 201341_at ENC1 212790_x_at RPL13A
211663_x_at PTGDS 204540_at EEF1A2 203797_at VSNL1 226131_s_at RPS16
205358_at GRIA2 215111_s_at TSC22D1 203999_at SYT1 209140_x_at HLA-B
205591_at OLFM1 209990_s_at GABBR2 200748_s_at FTH1 216526_x_at HLA-C
203151_at MAP1A 229606_at not found 200738_s_at PGK1 200716_x_at RPL13A
201034_at ADD3 221916_at NEFL 1556499_s_at COL1A1 212734_x_at RPL13
226018_at C7orf41 204337_at RGS4 212788_x_at FTL 204892_x_at EEF1A1
209123_at QDPR 225540_at MAP2 201360_at CST3 200781_s_at RPS15A
225275_at EDIL3 209470_s_at GPM6A 217728_at S100A6 211719_x_at FN1
203632_s_at GPRC5B 217897_at FXYD6 211959_at IGFBP5 214459_x_at HLA-C
203000_at STMN2 225111_s_at NAPB 208949_s_at LGALS3 211927_x_at not found
213841_at not found 215116_s_at DNM1 212624_s_at CHN1 201162_at IGFBP7
211071_s_at MLLT11 218309_at CAMK2N1 201012_at ANXA1 211911_x_at HLA-B
210222_s_at RTN1 202228_s_at NPTN 208636_at ACTN1 208812_x_at HLA-C
200795_at SPARCL1 204141_at TUBB2A 211980_at COL4A1 200031_s_at RPS11
230496_at FAM123A 200832_s_at SCD 222985_at YWHAG 200763_s_at RPLP1
225491_at SLC1A2 211458_s_at not found 204041_at MAOB 216442_x_at FN1
207547_s_at FAM107A 213841_at not found 201387_s_at UCHL1 211940_x_at not found
202242_at TSPAN7 209159_s_at NDRG4 204081_at NRGN 201029_s_at CD99
226913_s_at SOX8 221008_s_at AGXT2L1 216526_x_at HLA-C 213614_x_at EEF1A1
218309_at CAMK2N1 201116_s_at CPE 205970_at MT3 203034_s_at RPL27A
219549_s_at RTN3 211600_at PTPRO 209140_x_at HLA-B 201891_s_at B2M
211984_at CALM1 217963_s_at NGFRAP1 205029_s_at FABP7 213828_x_at not found
201242_s_at ATP1B1 219308_s_at AK5 202507_s_at SNAP25 210495_x_at FN1





























Table 45 CM1 Overexpressed genes, 1-VS-ALL 
PROBE ID GENE SYMBOL PROBE ID GENE SYMBOL PROBE ID GENE SYMBOL PROBE ID GENE SYMBOL
209875_s_at SPP1 211959_at IGFBP5 200665_s_at SPARC 227556_at NME7
224585_x_at ACTG1 201163_s_at IGFBP7 201033_x_at RPLP0 203798_s_at VSNL1
213214_x_at ACTG1 201012_at ANXA1 200026_at RPL34 202741_at PRKACB
200869_at not found 216231_s_at B2M 200099_s_at RPS3A 209242_at PEG3
212185_x_at MT2A 201162_at IGFBP7 214680_at NTRK2 212221_x_at IDS
210809_s_at POSTN 217733_s_at TMSB10 208856_x_at RPLP0 204229_at SLC17A7
208729_x_at HLA-B 200663_at CD63 211720_x_at RPLP0 210222_s_at RTN1
212363_x_at ACTG1 211911_x_at HLA-B 200717_x_at RPL7 209123_at QDPR
221798_x_at not found 209047_at AQP1 211666_x_at RPL3 200978_at MDH1
210512_s_at VEGFA 201721_s_at LAPTM5 215157_x_at PABPC1 204141_at TUBB2A
234989_at not found 204041_at MAOB 235308_at ZBTB20 229606_at not found
203107_x_at RPS2 1556499_s_at COL1A1 201670_s_at MARCKS 204337_at RGS4
210095_s_at IGFBP3 202018_s_at LTF 221731_x_at VCAN 202228_s_at NPTN
211980_at COL4A1 201105_at LGALS1 209292_at ID4 219308_s_at AK5
201984_s_at EGFR 217757_at A2M 212391_x_at RPS3A 201020_at YWHAH
210495_x_at FN1 208792_s_at CLU 214351_x_at RPL13 211458_s_at not found
212464_s_at FN1 211990_at HLA-DPA1 217897_at FXYD6 222985_at YWHAG
202649_x_at RPS19 212185_x_at MT2A 208692_at RPS3 205352_at SERPINI1
212433_x_at RPS2 209312_x_at not found 201254_x_at RPS6 225491_at SLC1A2
201105_at LGALS1 214459_x_at HLA-C 213158_at not found 203151_at MAP1A
200650_s_at LDHA 210512_s_at VEGFA 208986_at TCF12 215116_s_at DNM1
208949_s_at LGALS3 208812_x_at HLA-C 225897_at MARCKS 201242_s_at ATP1B1
216442_x_at FN1 221477_s_at SOD2 203382_s_at APOE 225111_s_at NAPB
216231_s_at B2M 215193_x_at not found 44783_s_at HEY1 211984_at CALM1
217733_s_at TMSB10 212063_at CD44 200062_s_at RPL30 204540_at EEF1A2
208812_x_at HLA-C 200838_at CTSB 212039_x_at RPL3 210198_s_at PLP1
211719_x_at FN1 216526_x_at HLA-C 213825_at OLIG2 207323_s_at MBP
205029_s_at FABP7 225353_s_at C1QC 215963_x_at not found 221916_at NEFL
201162_at IGFBP7 201666_at TIMP1 211073_x_at RPL3 201387_s_at UCHL1
213932_x_at HLA-A 213932_x_at HLA-A 227984_at not found 203000_at STMN2
213414_s_at RPS19 209140_x_at HLA-B 205383_s_at ZBTB20 229039_at SYN2
214459_x_at HLA-C 200839_s_at CTSB 224901_at SCD5 203130_s_at KIF5C
209140_x_at HLA-B 217728_at S100A6 222784_at SMOC1 202391_at BASP1
200663_at CD63 212464_s_at FN1 200787_s_at PEA15 211985_s_at CALM1
211911_x_at HLA-B 208306_x_at HLA-DRB1 202022_at ALDOC 201341_at ENC1
216438_s_at not found 209619_at CD74 221795_at NTRK2 221805_at NEFL
216526_x_at HLA-C 215313_x_at HLA-A 1569872_a_at not found 203485_at RTN1
215313_x_at HLA-A 210495_x_at FN1 201217_x_at RPL3 202260_s_at STXBP1
232541_at not found 213187_x_at FTL 211596_s_at LRIG1 212187_x_at PTGDS
201666_at TIMP1 212788_x_at FTL 203381_s_at APOE 205591_at OLFM1
211737_x_at PTN 234989_at not found 221796_at NTRK2 218309_at CAMK2N1
209466_x_at PTN 216442_x_at FN1 200788_s_at PEA15 202508_s_at SNAP25
224999_at not found 200748_s_at FTH1 209291_at ID4 211748_x_at PTGDS
202718_at IGFBP2 211719_x_at FN1 212667_at SPARC 209072_at MBP
209396_s_at CHI3L1 217767_at C3 219107_at BCAN 204081_at NRGN
203484_at SEC61G 201426_s_at VIM 213841_at not found 212624_s_at CHN1
205030_at FABP7 209396_s_at CHI3L1 205103_at C1orf61 202507_s_at SNAP25
209395_at CHI3L1 209395_at CHI3L1 228170_at OLIG1 227641_at FBXL16
201983_s_at EGFR 209875_s_at SPP1 209283_at CRYAB 203797_at VSNL1


































Table 47 Unique Gene IDs, down-regulated 
G1X G2X OX CX G2X-G1X G2X-G1X
GENE SYMBOL (41) GENE SYMBOL(40) GENE SYMBOL(42) GENE SYMBOL(28) GENESYMBOL (29) GENESYMBOL (36)
MBP RTN1 CHI3L1 VIM EGFR MBP
PTGDS SYT1 TMSB10 RPLP0 FABP7 PTGDS
PLP1 VSNL1 LDHA RPS2 SEC61G PLP1
FAM107A SNAP25 SERPINA3 RPS19 PTN FAM107A
RTN1 FBXL16 SPP1 RPL13 IGFBP2 TF
FBXL16 NRGN VIM SPARC POSTN FTH1
TF CALM1 FABP7 HLA-A CST3 SERPINA3
SNAP25 SLC1A2 TIMP1 CHI3L1 TRIB2 C3
BASP1 CHN1 IGFBP2 PTPRZ1 GNAS NTRK2
SYT1 ALDOC LGALS1 EGFR LGALS3 CRYAB
NTRK2 BASP1 SEC61G B2M VOPP1 PLEKHB1
ALDOC GABBR1 FN1 SERPINA3 PTPRZ1 FTL
VSNL1 STXBP1 VEGFA GNB2L1 HOPX SEPP1
PLEKHB1 BEX1 TUBB2A RPL13A HSPA8 PSAP
CHN1 OLFM1 CAMK2N1 RPLP2 NES CLDN11
NDRG2 NEFL FTL RPL39 IGFBP3 CLDND1
CRYAB TSPAN7 FABP5 RPS16 VIM NDRG2
KIF5C STMN2 CD63 HLA-B GNB2L1 RNASE1
NRGN ENC1 GAP43 HLA-C PPIA EDIL3
SCD SYN2 ENC1 EEF1A1 DBI ENPP2
STXBP1 RTN3 VSNL1 RPS15A LANCL2 CNP
GRIA2 GPM6A SYT1 FN1 EGR1 NME7
OLFM1 EEF1A2 FTH1 IGFBP7 S100A16 CD24
MAP1A TSC22D1 PGK1 RPS11 TMEM158 QDPR
ADD3 GABBR2 COL1A1 RPLP1 COL6A1 ADD3
C7orf41 RGS4 CST3 CD99 MALAT1 C7orf41
QDPR MAP2 S100A6 RPL27A JAG1 DNER
EDIL3 FXYD6 IGFBP5 ACTG1 RPS2 ATP1B1
GPRC5B NAPB LGALS3 TRIO APOE
STMN2 DNM1 CHN1 PFN2
MLLT11 CAMK2N1 ANXA1 CTSB
SPARCL1 NPTN ACTN1 SLC44A1
FAM123A TUBB2A COL4A1 GSN
SLC1A2 SCD YWHAG LAPTM5
TSPAN7 NDRG4 MAOB APOD


































Table 48 Unique Gene IDs, upregulated 
Genes  G1X G2X OX CX G1X-G2X G2X-G1X Total 
Downregulated Unique genes 41 40 42 28 29 36 216 
Not found 1 5 2 5 4 5 22 
Upregulated Unique genes 28 36 31 41 36 29 201 
Not found 6 3 5 2 5 4 25 
Table 49 Number of unique genes per class 
G1X G2X OX CX G2X-G1X G2X-G1X
GENE SYMBOL(28) GENE SYMBOL(36) GENE SYMBOL(31) GENE SYMBOL(41) UP (36) UP (29)
SPP1 IGFBP5 SPARC NME7 C1QC TRIO
ACTG1 IGFBP7 RPLP0 VSNL1 APOD RPS2
MT2A ANXA1 RPL34 PRKACB LAPTM5 JAG1
POSTN B2M RPS3A PEG3 APOE PPIA
HLA-B TMSB10 NTRK2 IDS GSN MALAT1
VEGFA CD63 RPL7 SLC17A7 SLC44A1 HSPA8
RPS2 HLA-B RPL3 RTN1 CTSB DBI
IGFBP3 AQP1 PABPC1 QDPR CLDND1 COL6A1
COL4A1 LAPTM5 ZBTB20 MDH1 PFN2 TMEM158
EGFR MAOB MARCKS TUBB2A ATP1B1 S100A16
FN1 COL1A1 VCAN RGS4 DNER EGR1
RPS19 LTF ID4 NPTN C7orf41 LANCL2
LGALS1 LGALS1 RPL13 AK5 ADD3 GNAS
LDHA A2M FXYD6 YWHAH CD24 GNB2L1
LGALS3 CLU RPS3 YWHAG QDPR VIM
B2M HLA-DPA1 RPS6 SERPINI1 NME7 IGFBP3
TMSB10 MT2A TCF12 SLC1A2 CNP NES
HLA-C HLA-C APOE MAP1A ENPP2 HOPX
FABP7 VEGFA HEY1 DNM1 EDIL3 PTPRZ1
IGFBP7 SOD2 RPL30 ATP1B1 FAM107A VOPP1
HLA-A CD44 OLIG2 NAPB FTL LGALS3
CD63 CTSB SCD5 CALM1 RNASE1 TRIB2
TIMP1 C1QC SMOC1 EEF1A2 NDRG2 CST3
PTN TIMP1 PEA15 PLP1 CLDN11 EGFR
IGFBP2 HLA-A ALDOC MBP PSAP POSTN
CHI3L1 S100A6 LRIG1 NEFL SEPP1 FABP7
SEC61G FN1 BCAN UCHL1 PTGDS IGFBP2
VIM HLA-DRB1 C1orf61 STMN2 PLEKHB1 PTN
CD74 OLIG1 SYN2 CRYAB SEC61G
FTL CRYAB KIF5C TF




































2) CM1 feature extraction diagrams 































Table 50 CM1 weights for top/bottom 50 1-vs-All 
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Although all the CM1 1-vs-1 sets have been extracted, only the G1X-vs-G2X has been 
considered relevant for the study by the bioinformatics expert doing the analysis. 























































































































Table 54 CM1 weights for G2X-vs-1 
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D. Hierarchical clustering linkage functions 
The linkage functions most commonly used in Hierarchical Clustering follows: 
 Single linkage: The new distance is the minimum distance among the two 
elements creating the cluster. 
 
Equation 23 Single linkage 
 Complete linkage: The new distance is the maximum distance among the two 
elements creating the cluster. 
 
Equation 24 Complete linkage 
 Average linkage: The new distance is the average pairwise distance among all 
the samples included in the two originating clusters. 
 
Equation 25 Average linkage 
This method inspired the below-mentioned Centroid linkage method and has been used 
successfully in [63] in analysis of gene expression data. 
 Weighted linkage: The new distance is the average distance from the two 
clusters (s, t) creating the new cluster (u) to the cluster (v) the distance is being 
calculated to. 
 
Equation 26 Weighted linkage 
A second group of linkage methods would include (among others) as defined in [64]: 
 Centroids linkage: The new distance is calculated as the distance among the 
centroids where the centroid is calculated from all the samples in the cluster. 
          
Equation 27 Centroid linkage 
 Median linkage: The new distance is calculated based on the distance of 
centroids but the new centroid is calculated based on the average of the two 
clusters (p, q) that were joined to create the cluster. 
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Equation 28 Median linkage 
 Ward linkage: The new distance, according to [26] “minimizes the information 
loss associated with clustering. Ward used an error sum-of-squares criterion to 
define information loss. At each step, union of every possible pair of clusters is 
considered and the two clusters whose fusion results in the smallest increase in 
‘information loss’ are combined. “.The formula as defined in [64]: 
 
Equation 29 Ward linkage 
 
E. Similarity and dissimilarity measures 
A common way of comparing the results of a classifier compared to the known true 
classification is the confusion matrix. It gives the number of samples that have been 
classified in each of the classes and this is intersected with its known class. Based on 
this, the values that are correctly classified will appear on the diagonal of the matrix 
while incorrect classified will be off-diagonal. Each Y, Z intersection will indicate 
how many class Y elements have been classified as class Z. While this concept is very 
intuitive and clear for classification problems it requires a further sophistication in 
order to be useful for clustering. The reason is that since clustering is some kind of 
unlabeled classifier, when there are disagreements it may not be possible to identify 
what is the part of the cluster that is correctly clustered. As an example, consider how 
to measure the correctness when for example one cluster has been split in two different 
clusters otherwise perfectly identified. 
To solve this problem, many of the similarity measures used for clustering are based 
on counting pair matches that is the number of pairs of samples that are in the same or 
different partition in the two partitions being compared. Four cases are considered, 
being P1 and P2 the compared partitions: 
 
 Same class in P2 Diff class in P2 
Same class in P1 a b 
Diff class in P2 c d 
 
where a is the number of pairs of samples in the same class in the two compared 
partitions, d is the number of pairs of samples  in different classes and  b, c correspond 
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respectively to the pairs in the same class in one partition that are not in the same class 
in the other.  
Indexes defined will have value 1 for matching partitions, meaning indexes measure 
the similarity of the two partitions. 
Metrics are the opposite concept, and measure the dissimilarity; therefore, they will 
have value 0 for matching partitions. 
1) Agreements and Disagreements  
Based on the “a, b, c, d” concepts defined previously the following indicators have 
been used: 
Same Class Agreements: corresponds to a, the number of pairs that are in the same 
class in the two partitions. 
Agreements: Corresponds to a + d, that is, pairs that are either in the same class in 
both partitions or elements that are not in the same partition in neither of the compared 
partitions. 
Disagreements: Corresponds to b + c, that is, the sum of the number of pairs that are 
in the same class in one partition but not in the other. 
The three indicators considered together are redundant since: 




N is the number of samples in the dataset. 
2) Jaccard Index 
The Jaccard Index was defined in [65]. Based on our introductory definition, the 
Jaccard Index can be defined as: 
    
 
     
 
Equation 30 Jaccard Index 
3) Fowlkes Mallows Index 
First defined in [66], based on our baseline definition, the formula is given by: 
    √
 
   
 
 
   
 
Equation 31 Fowlkes-Mallows Index 
4) Normalized Mutual Information Index 
It was defined in [67] and has two different normalizations possible, arithmetic and 
geometric. The arithmetic version is given by: 
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Equation 32 Normalized Mutual Information arithmetic 
 
The geometric version is defined in information theory terms as: 
         
      
√         
 
Equation 33 Normalized Mutual Information geometric 
where I(X,Y) is the mutual information: 
                   
Equation 34 Mutual Information 
and H(X) corresponds to entropy as defined in Equation 11. 
Alternativately, in clustering terms: 
         ∑∑        
      
    
 
   
 
   
 
Equation 35 Mutual Information for Clustering 
And xi is the number of samples in class i divided by the total number of samples, and 
xi,j is the number of samples in class i in the first partition and class j in the second 
partition. 
5) Normalized Mirkin Metric 
The Mirkin Metric was defined in [68], being his formula, as shown in [69]: 
 
Equation 36 Mirkin Metric 
where nx corresponds to the cluster x of the partition and nxy corresponds to the 
intersections of the two partitions.  
Its invariant (normalized) version is: 
 
Equation 37 Normalized Mirkin Metric 
being n the number of samples in the dataset. 
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6) Normalized Van Dongen Metric 
In [69], it is reported to be defined in . The formula is: 
 
Equation 38 Van Dongen Metric 
where the definition of nxy is analogous to the previous section. 
Again, the normalized version is given by: 
 
Equation 39 Normalized Van Dongen Metric 
7) Normalized Variation of Information Metric 
Variation of Information is defined in [70]: 
                 
Equation 40 Variation of Information 
It can be normalized, to make it bounded and not dependent on dataset size, in 
different ways, being 2 log N (VI upper bound ) the more advantageous as it is proved 
to be a metric (symmetric and satisfying the triangular inequality). 
         
             
     
 
Equation 41 Normalized Variation of Information 
8) Adjusted Rand Index 
The Rand Index(RI) [71], whose name is due to William Rand not to random numbers 
or anything alike,  is defined as:  
   
   
       
 
Equation 42 Rand Index 
It is bounded between 0 and 1, being 1 the value for two matching partitions.  
The Adjusted Rand Index (ARI) was defined in [72] as referred in [73]. Its formula is 
given by: 
 
Equation 43 Adjusted Rand Index 
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ni,j corresponds to the number of  samples in class i on the first partition and in class j 
in the second partition, ni. and n.j correspond to all the samples in class i of the first 
partition or class j of the second partition regardless the class on the other partition. If 
the confusion matrix of the two partitions was used, they would correspond to a whole 
row or column of the matrix. 
The concept is motivated in order to solve one limitation the Rand Index has. The 
limitation is that it would be expected Rand Index for two random partitions is 0 what 
is not the case.  
9) Purity 
While the concept is an old one and has appeared in many publications, it is best 
explained in [74]. It is defined formally as: 
            ∑
   
 
      
   





        
 
 
Equation 44 Purity 
In plain words, purity is the addition of the ratios of the dominant classes in each 
partition compared to a reference partition, typically the ground truth partition. 
Purity is [0, 1] bounded with 1 meaning perfect matching, and 0 complete 
dissimilarity. Purity is not a symmetric measure.  
Based on Purity and in order to obtain a symmetric measure, the F-measure is defined:  
               
                         
                        
 
Equation 45 F-Measure 
10) Homogeneity and Completeness 
Other information theory based measures are Homogeneity(h) and Completeness(c) 
defined in [59] as: 
       {
                               
  
      
    
         
 
Equation 46 Homogeneity 
 
       {
                              
  
      
    
         
 
Equation 47 Completeness 
where H(x) corresponds to the entropy as previously defined.  
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Homogeneity provides a measure of the content of each cluster, and is roughly 
proportional to the number of elements of the majority class in each cluster, 
conceptually similar to Purity. 
Completeness is the complementary concept, indicating the number of elements of one 
class that are not in other clusters. 
Still one more measure can be defined from h and c, the V-measure, defined as the 
harmonic mean of h and c: 
  
     
   
 
Equation 48 V-measure 
As explained in [70], the V measure has important drawbacks and favors partitions 
with a large number of clusters in particular the singleton partition (each element is a 
cluster). 
F. Data Normalization tests 
The normalization to sum to unity modifies it is not a linear one when considered 
among samples as it executed independently for each of the samples. Each data point 
is divided by the sum of the expressions of the probes in the sample, guaranteeing that 
the sum of the sample is the unity. 
To have an estimation of how this transformation affects the data a simple dataset has 
been generated. The dataset has 4 samples and 4 genes: 
  p1 p2 p3 p4 
g1 10 20 30 40 
g2 4 4 4 4 
g3 1000 2000 3000 4000 
g4 500 500 500 500 
Table 55 Synthetic dataset 
As can be observed the range for each of the genes are very different from each other. 
Note that g2 and g4 have the same value for all the samples. It would be desirable that 
any transformation applied maintain this. 
If the sum to unity normalization to each sample (p1-p4) is applied we obtain the 
following transformed dataset: 
  p1 p2 p3 p4 
g1 0.006605 0.007924 0.008489 0.008803 
g2 0.002642 0.001585 0.001132 0.00088 
g3 0.660502 0.792393 0.848896 0.880282 
g4 0.330251 0.198098 0.141483 0.110035 
Table 56 Column normalized dataset 
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Note that for g2, the values for p1 and p4, maximum and minimum respectively, have 
now a ratio of 3. Despite having a much higher initial value the ratio is the same for 
g4. The ratio for g1 compared with its original value ratio is also 3. 
If prior to applying the column normalization row normalization is applied, we obtain 
after the first transformation: 
  p1 p2 p3 p4 
g1 0.1 0.2 0.3 0.4 
g2 0.25 0.25 0.25 0.25 
g3 0.1 0.2 0.3 0.4 
g4 0.25 0.25 0.25 0.25 
Table 57 Dataset after row normalization 
And finally: 
  p1 p2 p3 p4 
g1 0.142857 0.222222 0.272727 0.307692 
g2 0.357143 0.277778 0.227273 0.192308 
g3 0.142857 0.222222 0.272727 0.307692 
g4 0.357143 0.277778 0.227273 0.192308 
Table 58 Dataset after subsequent row and column normalization 
In this case, the ratio between p1 and p4 for g2 and g4 is 1.85, much lower than when 
the data was only column normalized. Also for g1, compared to the original ratio 1:4 
as the initial values were different, is 1.85. 
Despite this evidence, without any formal validation to support further conclusions, it 
cannot be denied that the normalization is not an inconsequent transformation and may 
influence the final results, particularly, depending on the distance function used.  
When the distance function only considers the features in a 1-by-1 basis, such as 
Euclidean distance, the distance calculated will be affected. In the example, for the 
first case the distance is 0.311 and for the second case the distance is 0.329. The more 
important drawback is that distances that should be zero will not. 
In each case, all the pairwise comparisons among samples generate the same ratio for 
all the genes, indicating that the transformation applied while not affecting all the data 
points in the same way makes it consistently when pairwise considered. 
 
px to py p1 p2 p3 p4 
p1 1 0.599842 0.42841 0.333187 
p2 1.667107 1 0.714205 0.555458 
p3 2.334214 1.400158 1 0.777729 
p4 3.001321 1.800317 1.285795 1 




px to py p1 p2 p3 p4 
p1 1 0.777778 0.636364 0.538462 
p2 1.285714 1 0.818182 0.692308 
p3 1.571429 1.222222 1 0.846154 
p4 1.857143 1.444444 1.181818 1 
Table 60 Sample to sample norm factor for any gene with row-column normalization 
In cases like Pearson distance, what is being measured is not the distance among 
individual features but more the distance among features when these features are 
considered as part of the whole sample. A trivial example, the Pearson distance of any 
distribution respect to the same distribution linearly transformed is equal to 0.  
In the case of Jensen-Shannon divergence, what are being compared are the probability 
distributions, what keeps more similarities with the Pearson scenario that with the 
Euclidean distance scenario. In addition, one of the properties said that the JSD was 
zero only if the two distributions were identical, therefore, we may expect different 
results for the two normalizations described. 
Finally, computing the distance matrix for the two cases it can be observed that the 
matrixes have different values and also slightly different distributions, Table 3. Hence, 
generating different results for the two normalizations may depend not only on the data 
but also on the clustering algorithm in place. 
G. Brain tumour diagnosis reliability 
The reliability of tumor diagnosis has been subject of study. Two recent studies are 
[75] and [76]. On the studies, the consensus of diagnosis of glioma patients is 
evaluated based on observed significant inter-observer variation of glioma. The 
diagnosis is variant in both typing and grading of the gliomas.  
The first study mentions that from 500 brain tumors reviewed, 42.8% show some 
diagnosis disagreement that can be considered serious in 8.8%. The study refers to 
other studies mentioning that this misdiagnose is higher when the patient proceeds 
from local community hospitals as opposed to academic hospitals. 16% of the 
discordant diagnoses were clinically significant as were affecting treatment and/or 
prognosis. A study of 244 cases with intervention of four pathologists showed 52% 
initial agreement that grew to 62% after the fourth round of reviews. 
Oligodendrogliomas became a 25% of the diagnosis while initially they were only 5%. 
The list of studies reviewed goes mentioning that among the different know glioma 
types there are mixed types such as oligoastrocytomas making the diagnosis criteria 
blurrier with only 13% agreement for those cases. One preliminary conclusion of the 
study is that among 20 to 30% of gliomas are reclassified based on independent 
reviews. 
The second study, focused on different diagnosis criteria and its changing definition 
along the years, explains the difficulty of diagnosis in the small series of 
oligodendroglioma tumors available. The same study mentions that some criteria are 
universally accepted as indicator of a glioma. About diagnosis variability, the study 
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mentions that only 36% cases of Astrocytoma (AA) are confirmed. For Glioblastoma 
this ratio raised to 73% indicating more robust clinic diagnostic criteria. Only 32% 
majority and 8% consensus was achieved for Oligoastrocytoma (OA). 
H. Known results obtained from dataset GSE4290 
In [42], the original study that made available the dataset, the main conclusions are 
related to only one gene, SCF(Stem Cell Factor). The study combines the analysis of 
the genetic information in Micro Array data with other tests so the information is of 
limited use for comparing with the current results. 
In [77], the same dataset has been used obtaining a list of modules (MEA) and the 
corresponding up-regulated or down-regulated groups. 
 
Table 61 Results in [77] showing MEA 
In [78], CLIC, the algorithm developed as part of the study is not capable of dealing 
with all genetic information(>40K genes), while for others algorithms compared the 
threshold was even lower. 
In [41], the method permits to obtain a classification of the samples with 56% accuracy 
on average using a set of 44 genes selected with a different dataset (training set) and 
capable of dealing with higher accuracy if the training is performed with two or more 
datasets from independent studies. Only GBM (77 samples) and OLG (50 samples)  














Table 62 11 GB serum markers 
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When the dataset was used to train a model and the obtained model tested with other 
datasets, the accuracy was an average 40.66%. When other datasets were used for 
training and the dataset used to test the accuracy was 72.08%. 
To differentiate GBM from OLG the cut of the genes 1p and 19q becomes a marker as 
it is the Olig2 over-expression. GBM and A3 are differentiated based on the 
expression of FLNA, ANXA1, and bHLH. IDH is another biomarker for GBM. EPN 
gliomas are differentiated from other types based on TLE4, OLIG2. 
In [79], the GSE4290 dataset is used in a classification of the patients in 1-vs-1 groups 
(GBM-vs-OLG and GBM-vs-AC), Figure 26. The experiment is done as part of a 
study to improve the prognosis profiles for gliomas, Figure 27. The study, that is based 
on several datasets, concludes that 42 probes are relevant based on a multivariate Cox 
statistical. In the case of our dataset the 42 probes are specific for lower grade gliomas 
and group 3 GBM. 
 




Figure 27 GSE4290 Prognosis classification 
  
Table 63 42 Probesets relevant for glioma prognosis 
In [80], 78 genes, shown in Table 64, where selected to differentiate glioma-relevant 
gliogenesis genes. The genes where selected based on differential expression after 




















































































Table 64 List of gliogenesis related genes as in [80] 
In [81], while a different dataset has been used, a 90 genes profile has been defined in 
order to differentiate among different types of glioblastomas. 
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